SNDL (SNDL) 20-F 24 Apr 23 2022 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	SNDL Inc.
Entity Central Index Key	0001766600
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Incorporation, State or Country Code	A0
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	235,194,236
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Trading Symbol	SNDL
Security Exchange Name	NASDAQ
Entity File Number	001-39005
Entity Address, State or Province	AB
Entity Address, Address Line One	#300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
Entity Address, Country	CA
Document Annual Report	true
Document Transition Report	false
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	Marcum	KPMG
Auditor Location	New York, New York, United States	Calgary, Alberta, Canada
Auditor Firm ID	688	85
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
City Area Code	403
Local Phone Number	948-5227
Entity Address, Country	CA
Contact Personnel Name	James Keough
Contact Personnel Email Address	investors@sndl.com

Consolidated Statements of Fina

Consolidated Statements of Financial Position $ in Thousands, $ in Millions		Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)
Current assets
Cash and cash equivalents		$ 279,586	$ 558,251	[1]
Restricted cash		19,338	27,013	[1]
Marketable securities		21,926	83,724	[1]
Accounts receivable		22,636	10,865	[1]
Biological assets		3,477	4,410	[1]
Inventory		127,782	29,503	[1]
Prepaid expenses and deposits		10,110	4,355	[1]
Investments		6,552	3,065	[1]
Assets held for sale		6,375	2,998	[1]
Net investment in subleases		3,701	3,991	[1]
Current assets		501,483	728,175	[1]
Non-current assets
Long-term deposits		8,584	7,725	[1]
Right of use assets		134,154	6,717	[1]
Property, plant and equipment		143,409	56,472	[1]
Net investment in subleases		19,618	22,571	[1]
Intangible assets	[1]	74,885	50,148
Investments		90,702	70,498	[1]
Equity-accounted investees		519,255	412,858	[1]
Goodwill	[1]	67,260	72,496
Total assets		1,559,350	1,427,660	[1],[2]
Current liabilities
Accounts payable and accrued liabilities		48,153	38,452	[1]
Current lease liabilities		30,206	5,701	[1]
Derivative warrants		11,002	21,700	[1]
Current liabilities		89,361	65,853	[1]
Non-current liabilities
Lease liabilities		139,625	27,769	[1]
Other liabilities		2,709	4,505	[1]
Total liabilities		231,695	98,127	[1]
Shareholders’ equity
Share capital		2,292,810	2,035,704	[1]
Warrants		2,260	8,092	[1]
Contributed surplus		68,961	60,734	[1]
Contingent consideration		2,279	2,279	[1]
Accumulated deficit	[1]	(1,091,999)	(785,112)
Accumulated other comprehensive income		32,188	7,607	[1]
Total shareholders’ equity		1,306,499	1,329,304	[1]
Non-controlling interest		21,156	229	[1]
Total liabilities and shareholders’ equity		$ 1,559,350	$ 1,427,660	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b)

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Statement of comprehensive income [abstract]
Gross revenue		$ 729,694		$ 67,279	[1]	$ 73,321
Excise taxes		17,497		11,151	[1]	12,403
Net revenue		712,197		56,128	[1]	60,918
Cost of sales	[1]	558,089		50,612		51,740
Inventory impairment and obsolescence		7,012		16,978	[1]	45,913
Gross margin before fair value adjustments		147,096		(11,462)	[1]	(36,735)
Change in fair value of biological assets		(1,309)		4,708	[1]	5,432
Change in fair value realized through inventory		(5,412)		(2,247)	[1]	(18,566)
Gross margin		140,375		(9,001)	[1],[2]	(49,869)
Interest and fee revenue		16,739		13,149	[1]	0
Investment loss		(65,164)		(44,501)	[1]
Share of profit (loss) of equity-accounted investees		(43,002)		32,913	[1]	0
General and administrative	[1]	140,168		38,043		32,029
Sales and marketing		8,417		5,043	[1]	5,737
Research and development		2,448		2,446	[1]	488
Depreciation and amortization	[1]	40,945		5,287	[2]	4,711
Share-based compensation		9,671		12,307	[1]	8,566
Restructuring costs		(670)		874	[1]	6,470
Asset impairment		196,033		60,000	[1]	79,191
Government subsidies				(2,180)	[1]	(4,128)
Loss (gain) on cancellation of contracts		(290)		5,116	[1]	2,471
Loss from operations		(347,774)		(134,376)	[1]	(185,404)
Transaction costs		(1,352)		(17,566)	[1]	(3,587)
Finance costs, net		(41,314)		(3,756)	[1]	(3,819)
Change in estimate of fair value of derivative warrants		10,783		(77,834)	[1]	(12,995)
Foreign exchange gain (loss)		(19)		531	[1]	(1,000)
Gain (loss) on disposition of assets		(94)		235	[1]	488
Other expenses	[1]			(1,932)
Loss before income tax		(379,770)		(234,698)	[1],[2]	(206,317)
Income tax recovery	[1]	7,342		7,914
Net loss from continuing operations		(372,428)	[3]	(226,784)	[1]	(206,317)	[3]
Net loss from discontinued operations						(33,627)
Net loss		(372,428)		(226,784)	[1]	(239,944)
Equity-accounted investees - share of other comprehensive income, net of tax		24,581		7,607	[1]
Gain on translation of foreign operations						600
Comprehensive loss		(347,847)		(219,177)	[1]	(239,344)
Net loss from continuing operations attributable to:
Owners of the company	[1]	(335,114)		(226,984)		(199,619)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Net loss from continuing operations		(372,428)	[3]	(226,784)	[1]	(206,317)	[3]
Net income (loss) attributable to:
Owners of the company	[1]	(335,114)		(226,984)		(233,246)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Net loss		(372,428)		(226,784)	[1]	(239,944)
Comprehensive income (loss) attributable to:
Owners of the company	[1]	(310,533)		(219,377)		(232,646)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Comprehensive loss		$ (347,847)		$ (219,177)	[1]	$ (239,344)
Net loss per common share attributable to owners of the company
Basic and diluted		$ (1.46)		$ (1.22)	[1]	$ (10.67)
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b) Adjustment to provisional amounts — refer to note 5(b) .

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total		Share Capital	Warrants	Contributed Surplus	Contingent Consideration	Accumulated Deficit	[1]	Accumulated Other Comprehensive income	Non-controlling interests [member]
Beginning balance at Dec. 31, 2019	$ 221,198		$ 509,654	$ 27,831	$ 30,192	$ 2,279	$ (360,338)		$ 6,866	$ 4,714
Net loss	(239,944)						(233,246)			(6,698)
Other comprehensive income	600								600
Share issuances	176,931		176,931
Share issuance costs	(5,593)		(5,593)
Derivative warrants exercised	55,912		55,912
Convertible debt - conversions	63,002		63,002
Warrants issued	306			306
Warrants expired				(21,999)	21,999
Dispositions	(10,457)		(38,447)				35,456		(7,466)
Share-based compensation	7,740		52		7,688
Employee awards exercised			535		(535)
Ending balance at Dec. 31, 2020	269,695		762,046	6,138	59,344	2,279	(558,128)			(1,984)
Net loss	(226,784)	[2]					(226,984)			200	[1]
Other comprehensive income	7,607								7,607
Loss of control of subsidiary	2,013									2,013
Share issuances	977,425		977,425
Share issuance costs	(16,371)		(16,371)
Derivative warrants exercised	277,136		277,136
Acquisition	27,987		26,216	1,771
Convertible debenture settlement	2,671		2,671
Convertible debt - conversions			2,671
Warrants issued	361			361
Warrants exercised			178	(178)
Share-based compensation	12,723		8		12,715
Employee awards exercised	201		6,395		(6,194)
Modification of equity-settled plan	(5,131)				(5,131)
Ending balance at Dec. 31, 2021	1,329,533		2,035,704	8,092	60,734	2,279	(785,112)		7,607	229
Net loss	(372,428)						(335,114)			(37,314)
Other comprehensive income	24,581								24,581
Share issuances	2,870		2,870
Share repurchases	(13,390)		(41,617)				28,227
Share issuances by subsidiaries	115				72					43
Share issuance costs			0
Derivative warrants exercised			0
Acquisition	345,351		287,129							58,222
Convertible debt - conversions			0
Warrants exercised			0
Warrants expired				(5,832)	5,832
Share-based compensation	11,047				11,047
Employee awards exercised			8,724		(8,724)
Distribution declared by subsidiaries	(24)									(24)
Ending balance at Dec. 31, 2022	$ 1,327,655		$ 2,292,810	$ 2,260	$ 68,961	$ 2,279	$ (1,091,999)		$ 32,188	$ 21,156
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Operating activities
Net loss from continuing operations for the period		$ (372,428)	[1]	$ (226,784)	[2]	$ (206,317)	[1]
Items not involving cash:
Income tax recovery	[1]	(7,342)		(7,914)		0
Interest and fee revenue		(16,739)		(13,149)	[2]	0
Change in fair value of biological assets		1,309		(4,708)	[1]	(5,432)
Share-based compensation		9,671		12,307	[1]	8,566
Depreciation and amortization	[1]	47,322		10,164		11,582
Loss (gain) on disposition of assets		94		(235)	[1]	(488)
Inventory obsolescence		7,012		16,978	[1]	45,913
Finance costs		41,314		3,716	[1]	(3,734)
Change in estimate of fair value of derivative warrants		(10,783)		77,834	[2]	12,995
Loss on cancellation of contracts		0		2,870	[1]	671
Unrealized foreign exchange (gain) loss		(16)		(63)	[1]	(757)
Restructuring costs		0		0	[1]	448
Warrants issued for services		0		0	[1]	306
Asset impairment		196,033		60,000	[2]	79,191
Share of (profit) loss of equity-accounted investees		43,002		(32,913)	[2]	0
Other expenses		0		1,864	[1]	0
Gain on disposition of marketable securities		0		(20,213)	[1]	0
Unrealized loss on marketable securities		65,553		64,714	[1]	0
Additions to marketable securities		(3,500)		(158,101)	[1]	0
Proceeds from disposal of marketable securities		0		29,876	[1]	0
Income distributions from equity-accounted investees		1,661		15,021	[1]	0
Interest received		13,403		0	[1]	0
Exercise of cash-settled deferred share units		(204)		(315)	[1]	0
Change in non-cash working capital		(22,073)		150	[1]	(5,259)
Net cash used in operating activities from continuing operations		(6,711)		(155,752)	[1]	(62,315)
Net cash provided by operating activities from discontinued operations		0		0	[1]	4,820
Net cash used in operating activities		(6,711)		(155,752)	[1]	(57,495)
Investing activities
Additions to property, plant and equipment		(10,666)		(3,793)	[1]	(3,024)
Additions to intangible assets		(197)		0	[1]	(150)
Additions to investments		(75,598)		(24,206)	[1]	(51,876)
Additions to equity-accounted investees		(119,137)		(395,569)	[1]	0
Capital distributions from equity-accounted investees		0		10,481	[1]	0
Proceeds from disposal of property, plant and equipment		4,000		194	[1]	2,109
Acquisition, net of cash acquired		(28,640)		(82,775)	[1]	0
Change in non-cash working capital		74		(612)	[1]	(11,319)
Net cash used in investing activities from continuing operations		(230,164)		(496,280)	[1]	(64,260)
Net cash used in investing activities from discontinued operations		0		0	[1]	(6,617)
Net cash used in investing activities		(230,164)		(496,280)	[1]	(70,877)
Financing activities
Proceeds from convertible notes, net of costs		0		0	[1]	18,070
Change in restricted cash		7,675		(21,680)	[1]	10,494
Payments on lease liabilities, net		(27,693)		(1,008)	[1]	(420)
Repurchase of common shares, net of costs		(13,390)		0	[1]	0
Proceeds from issuance of shares and registered offerings, net of costs		22		1,062,310	[1]	181,841
Distributions declared by subsidiaries		(24)		0	[1]	0
Proceeds from exercise of derivative warrants		0		119,318	[1]	20,391
Proceeds from exercise of employee warrants		0		201	[1]	0
Repayment of long-term debt		(10,000)		0	[1]	(84,493)
Convertible debenture settlement		0		(9,354)	[1]	0
Payment on exercise of contingent consideration warrants		0		(219)	[1]	0
Change in non-cash working capital		1,620		348	[1]	(2,498)
Net cash (used in) provided by financing activities from continuing operations		(41,790)		1,149,916	[1]	143,385
Net cash used in financing activities from discontinued operations		0		0	[1]	(639)
Net cash (used in) provided by financing activities		(41,790)		1,149,916	[1]	142,746
Effect of exchange rate changes on cash held in foreign currency		0		(9)	[1]	665
Change in cash and cash equivalents		(278,665)		497,875	[1]	15,039
Cash and cash equivalents, beginning of year		558,251	[3]	60,376	[1]	45,337
Cash and cash equivalents, end of year		$ 279,586		$ 558,251	[3]	$ 60,376	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Description Of Business [Abstract]
Description of Business	1. Description of business SNDL Inc. (“SNDL” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company’s shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from “Sundial Growers Inc.” to “SNDL Inc.”. The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada. The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. (“Nova”) (TSX: NOVC), whose principal activities are the retail sale of cannabis. SNDL and its subsidiaries currently operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. (“SunStream”) (note 17), the Company provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities. The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2022
Disclosure Of Basis Of Presentation [Abstract]
Basis of Presentation	2. Basis of presentation a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2022. These consolidated financial statements were approved and authorized for issue by the board of directors of SNDL (the “Board”) on April 24, 2023. b) Basis of measurement These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, deferred share units (“DSUs”) and certain financial instruments (note 31(a)) which are measured at fair value with changes in fair value recorded in earnings. c) Functional and presentation currency These consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its Canadian-based subsidiaries. Sundial Deutschland GmbH uses the European Euro as its functional currency. The Company’s equity-accounted joint venture uses the United States dollar as its functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions. In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries and the foreign equity-accounted joint venture are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign operations that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries and the foreign equity-accounted joint venture into Canadian dollars are recognized in other comprehensive income (“OCI”). The Company’s consolidated financial statements include its share of the Canadian dollar profit or loss and OCI of the equity-accounted joint venture. d) Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances, income and expenses and unrealized gains and losses resulting from intercompany transactions are eliminated upon consolidation.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. CASH AND CASH EQUIVALENTS Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days. RESTRICTED CASH Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading positions, if any, and (ii) minimum funding requirements for two separate captive insurance structures. BIOLOGICAL ASSETS The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour-related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture (“IAS 41”) and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods. INVENTORY Harvested cannabis Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour-related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. Retail inventory Retail inventory at Company-owned stores is valued at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined using the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels. PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized. Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates. Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in profit and loss. PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained, if required for operation. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below: • Production facilities — 20 years • Equipment — 1 to 10 years • Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term INTANGIBLE ASSETS Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with International Accounting Standard 38 – Intangible Assets (“IAS 38”). The Company’s intangible assets are comprised of the following: • Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years. • Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years. • Intellectual property acquired through the acquisition of Inner Spirit (as defined below) consisting of a trade name with an indefinite life and franchise agreements with useful lives of 8 years. • Intangible assets acquired through the acquisition of Alcanna consisting of brands, licenses, permits and software. Joint arrangements Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets. For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases. Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid. Interests in equity-accounted investees The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture. Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities. Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases. IMPAIRMENT OF ASSETS Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining and maintaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates. (i) Financial assets The Company applies an expected credit loss (“ECL”) model to all financial assets not held at fair value through profit and loss (“FVTPL”) where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under International Financial Reporting Standard 9 – Financial Instruments (“IFRS 9”) and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECLs are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information. (ii) Non-financial assets The carrying amounts of the Company’s PP&E, right of use assets and intangible assets, including goodwill, are assessed for impairment indicators and impairment reversal indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment or impairment reversal. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss or impairment reversal, if any. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of asset’s estimated fair value less costs of disposal and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit (“CGU”)). Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset or CGU is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized previously. A reversal of an impairment loss, net of any depreciation that would have been recorded, is recognized immediately in the statements of loss and comprehensive loss. Impairments of goodwill are not reversed. FINANCIAL INSTRUMENTS The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments: Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance. (i) Financial assets At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or fair value through other comprehensive income (“FVOCI”) depending on the business model and contractual cash flows of the instrument. Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss. The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at FVOCI. (ii) Financial liabilities Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss. Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt. The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition. Provisions A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2022 and 2021. NON-MONETARY TRANSACTIONS All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value. COMPOUND FINANCIAL INSTRUMENTS The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition. Interest and losses and gains relating to the financial liability are recognized in profit and loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion. REVENUE Under International Financial Reporting Standard 15 – Revenue from Contracts with Customers (“IFRS 15”), to determine the amount and timing of revenue to be recognized, the Company follows a five-step model: 1. Identifying the contract with a customer 2. Identifying the performance obligations 3. Determining the transaction price 4. Allocating the transaction price to the performance obligations 5. Recognizing revenue when/as performance obligations are satisfied Cannabis revenue Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods. For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly. Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing. Retail revenue Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives. It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift card. The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price. Franchise revenue Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits. Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and stewarding the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they utilize the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements. Other revenue Proprietary licensing revenue is generated from proprietary licensing services provided to customers. Revenue is recognized when the services are delivered to the customer at a point in time as outlined by the contract. The Company does not operate or manage these services separately from its primary retail sales or operations. Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner. Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped. RESEARCH AND DEVELOPMENT Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38. Research and development costs comprise consulting fees, costs to cultivate and test cultivar batches to the point of commercialization and licence acquisition fees. No development costs have been capitalized as at December 31, 2022, or December 31, 2021. SHARE-BASED COMPENSATION The Company’s share-based compensation plans include equity-settled awards and cash-settled awards. The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted. Equity-settled Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted from time to time to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital. Cash-settled DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment. Nova DSUs are granted to Nova directors and represent a right for the holder to receive a cash payment equal to the fair value of Nova’s common shares calculated at the date of such payment, or Nova common shares, at the discretion of Nova. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur. INCOME TAXES Income taxes are recognized in profit and loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity. Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and include any adjustment to income tax payable or recoverable in respect of previous periods. Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable. Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized. Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected. BUSINESS COMBINATIONS Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities

Significant Accounting Estimate

Significant Accounting Estimates, Assumptions and Judgements	12 Months Ended
	Dec. 31, 2022
Disclosure of initial application of standards or interpretations [abstract]
Significant accounting estimates, assumptions and judgements	4. Significant accounting estimates, assumptions and judgements The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated. Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected. Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following: IMPAIRMENTS CGU’s are defined as the lowest grouping of integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructure and the way in which management monitors the Company’s operations. The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licences from Health Canada, total addressable market, market share escalation factor, gross margin escalation factor, terminal multiple and discount rates. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s. BIOLOGICAL ASSETS AND INVENTORY Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest. Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged. Revenue Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in some cases, have a right of product return or warranty period. The estimate of potential future returns includes the use of estimates and assumptions and are subject to change as new information becomes available. CONVERTIBLE INSTRUMENTS The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors. ACQUISITIONS The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under International Financial Reporting Standard 3 – Business Combinations (“IFRS 3”). This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes. Investments The Company’s investments at FVTPL are financial assets measured at fair value each reporting period. The determination of the fair value of each investment requires judgement from management and the primary assumption is the discount rate. equity-accounted investees The Company’s interest in a joint venture is accounted for using the equity-method. The current investment portfolio of the joint venture is comprised of secured debt and hybrid instruments which include options and warrants. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. The determination of the fair value of the underlying investments is based on a discounted cash flow methodology and requires judgement from management. The discounted cash flows are based on various assumptions, including an estimation of market prices, volatility and discount rates.

Business Acquisitions

Business Acquisitions	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about business combination [abstract]
Business Acquisitions	5. Business acquisitions a) Alcanna On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company would acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022 , and the Alcanna Transaction closed on March 31, 2022 . Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximate 63 % equity interest in Nova, a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario, under its “Value Buds” and “Sweet Tree” retail brands. The Company is deemed to control Nova through its equity interest and Nova’s results are included in the consolidated financial statements of the Company with the minority interest shown as non-controlling interest through equity. Alcanna was acquired to diversify and stabilize cash flows and advance the Company’s vertical integration strategy. The Alcanna Transaction consideration was comprised of (i) an aggregate $ 54.3 million cash ($ 1.50 in cash for each Alcanna common share), and (ii) an aggregate 32.1 million SNDL common shares valued at $ 287.1 million based on the fair value of each common share of the Company on the closing date ( 0.885 of a SNDL common share for each Alcanna common share). The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any. The fair value of consideration paid was as follows: Provisional Adjustments Final Cash 54,339 — 54,339 Issuance of common shares 287,129 — 287,129 341,468 — 341,468 The fair value of the assets and liabilities acquired was as follows: Provisional Adjustments Final Cash 23,190 — 23,190 Accounts receivable 1,868 — 1,868 Prepaid expenses and deposits 10,986 — 10,986 Inventory 105,022 — 105,022 Right of use assets 171,866 ( 31,117 ) 140,749 Property, plant and equipment 86,059 24,632 110,691 Intangible assets — 45,100 45,100 Goodwill 280,243 ( 129,308 ) 150,935 Accounts payable and accrued liabilities ( 36,703 ) ( 44 ) ( 36,747 ) Long-term debt ( 10,000 ) — ( 10,000 ) Lease liabilities ( 232,755 ) 90,736 ( 142,019 ) Derivative warrants ( 58 ) ( 27 ) ( 85 ) Non-controlling interest ( 58,250 ) 28 ( 58,222 ) 341,468 — 341,468 Non-controlling interest has been measured as the fair value of the non-controlling interest in Nova, which at the time was 37 %, and was measured by applying a market approach with reference to Nova’s closing share price on the day of the Alcanna Transaction of $ 2.66 . On March 31, 2022, the Company repaid in full the acquired long-term debt balance of $ 10.0 million. These consolidated financial statements incorporate the operations of Alcanna commencing March 31, 2022. During the period March 31, 2022 to December 31, 2022, the Company recorded revenu es of $ 639.5 mi llion and net loss of $ 101.0 million from the Alcanna operations. Had the Alcanna Transaction closed on January 1, 2022, management estimates that for the period January 1, 2022, to March 30, 2022, revenue would have increased by $ 162.5 million and net loss would have increased by $ 25.5 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022. The Company incurred costs related to the Alcanna Transaction of $ 7.0 million which have been included in transaction costs. The Company recorded adjustments to the fair value in the fourth quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of right of use assets, property, plant and equipment, intangible assets, accounts payable and accrued liabilities, lease liabilities, derivative warrants and non-controlling interest. All measurement period adjustments were offset to goodwill. goodwill impairment For the purpose of impairment testing at December 31, 2022, intangible assets with indefinite lives were allocated to the Company’s CGUs as follows: i) $ 2.7 million to the cannabis retail CGU, ii) $ 18.3 million to the cannabis franchise CGU and iii) $ 43.1 million to the liquor retail CGU. Goodwill from the Alcanna acquisition was allocated as follows: i) $ 126.6 million to the cannabis retail CGU and ii) $ 24.3 million to the liquor retail CGU. The remaining goodwill from the Inner Spirit acquisition of $ 4.6 million was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s cannabis retail CGU used its fair value less costs of disposal and the fair value measurement was categorized as a Level 1 fair value based on the inputs in the valuation technique used. The impairment test for the Company’s cannabis franchise and liquor retail CGUs used a value in use approach based on internal cash flow estimates at December 31, 2022, and a discount rate of 12.0 %. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis and liquor industry market sizes and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $ 88.0 million as at December 31, 2022 as the estimated recoverable amount for this CGU of $ 84.8 million was lower than the respective carrying amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment. b) Inner Spirit On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021 . Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that included more than 100 franchised and corporate-owned locations at the acquisition date. The Inner Spirit Transaction consideration was comprised of (i) an aggregate $ 92.6 million cash ($ 0.30 in cash for each Inner Spirit common share), (ii) an aggregate 2.4 million SNDL common shares valued at $ 26.2 million based on the fair value of each common share of the Company on the closing date ( 0.00835 of a SNDL common share for each Inner Spirit common share) and (iii) contingent consideration valued at $ 1.2 million representing the fair value of Inner Spirit warrants. The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts. The fair value of consideration paid was as follows: Provisional Adjustments Final Cash 92,583 — 92,583 Issuance of common shares 26,216 — 26,216 Contingent consideration 1,150 — 1,150 119,949 — 119,949 The fair value of the assets and liabilities acquired was as follows: Provisional Adjustments Final Cash 9,808 — 9,808 Accounts receivable 750 ( 327 ) 423 Prepaid expenses and deposits 853 — 853 Inventory 2,733 2,011 4,744 Right of use assets — 5,730 5,730 Property, plant and equipment 12,108 ( 5,730 ) 6,378 Intangible assets — 46,000 46,000 Net investment in subleases 23,751 50 23,801 Goodwill 114,537 ( 42,041 ) 72,496 Accounts payable and accrued liabilities ( 2,678 ) — ( 2,678 ) Convertible debentures ( 12,025 ) — ( 12,025 ) Lease liabilities ( 29,481 ) ( 50 ) ( 29,531 ) Financial guarantee liability ( 407 ) — ( 407 ) Deferred tax liability — ( 5,643 ) ( 5,643 ) 119,949 — 119,949 On August 4, 2021, the Company settled the convertible debenture liability through the issuance of 2.5 million common shares valued at $ 2.7 million and a cash payment of $ 9.3 million. Due to the change of control from the Inner Spirit Transaction, debenture holders were entitled to receive SNDL common shares and a cash payment based on a prescribed formula. The fair value of the Inner Spirit warrants has been estimated as $ 1.2 million and is made up of the following components: (i) equity component of $ 1.8 million (note 23(c)), (ii) liability component of $ 0.3 million and (iii) asset component of $ 0.9 million. The consolidated financial statements incorporate the operations of Inner Spirit commencing July 20, 2021. During the period July 20, 2021, to December 31, 2021, the Company recorded revenues of $ 16.1 million and net earnings of $ 1.1 million. Had the acquisition closed on January 1, 2021, management estimates that for the period January 1, 2021, to July 19, 2021, revenue would have increased by $ 20.4 million and net earnings would have been reduced by $ 7.4 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2021. The Company incurred acquisition-related costs of $ 1.9 million which have been included in transaction costs. The Company recorded adjustments to the fair value in the third quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of accounts receivable, inventory, net investment in subleases, lease liabilities and amounts allocated to intangible assets and deferred tax liability. All measurement period adjustments were offset to goodwill. The Company made retrospective adjustments to provisional amounts in the comparative period as follows: • The carrying amount of intangible assets as at December 31, 2021 was increased by $ 45.4 million, representing the increase in fair value of $ 46.0 million less additional amortization from the acquisition date to December 31, 2021 of $ 0.6 million. • The deferred tax liability of $ 5.6 million was adjusted to nil with a corresponding adjustment recorded to income tax recovery, on the basis that the Company and Inner Spirit are subject to income tax under the same taxation authority. • Amortization expense for 2021 was increased by $ 0.6 million (Q3 2021 — $ 0.3 million and Q4 2021 — $ 0.3 million). • Cost of sales for 2021 was increased by $ 2.0 million, representing the increase in fair value of acquired inventory that was sold during 2021. • General and administrative expenses was decreased by $ 0.3 million, representing the decrease in fair value of acquired accounts receivable. • Goodwill was decreased by $ 42.0 million. Inner Spirit goodwill and intangible asset impairment For the purpose of impairment testing at September 30, 2022, intangible assets with indefinite lives consisting of the Inner Spirit brands and trademarks were allocated to the Company’s CGUs as follows: i) $ 17.7 million to the cannabis retail CGU and ii) $ 18.3 million to the cannabis franchise CGU. The impairment test for the Company’s cannabis retail and cannabis franchise CGUs used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5 %. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $ 16.4 million as at September 30, 2022 as the estimated recoverable amount for this CGU of $ 1.9 million was lower than the respective carrying amount. T he impairment loss was fully allocated to intangible assets with indefinite lives and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment. For the purpose of impairment testing at September 30, 2022, goodwill of $ 72.5 million from the Inner Spirit acquisition was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s group CGU used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5 %. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s group CGU of $ 67.9 million as at September 30, 2022 as the estimated recoverable amount for this group CGU of $ 40.0 million was lower than the respective carry ing amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The estimated value in use for the Company’s group CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1 % would increase the impairment by approximately $ 1.1 million. The impairment was recognized in the Company’s cannabis retail reportable segment. c) Zenabis On November 1, 2022, the Company announced that, in the context of proceedings pursuant to the Zenabis Group’s (as defined below) filing under the Companies’ Creditors Arrangement Act (“CCAA”), it had successfully acquired all of the assets of the business of the Zenabis Group, subject to certain exclusions, (the “Zenabis Business”), pursuant to an approval order of the Québec Superior Court (the “Court”). The order of the Court approved the acquisition by a wholly owned subsidiary of SNDL of all issued and outstanding shares of Zenabis Ltd., a corporation resulting from the amalgamation of select Zenabis entities (collectively, the “Zenabis Group”), as part of the consideration for the senior secured debt of the Zenabis Group due to the SNDL subsidiary. Zenabis Ltd. owns all of the Zenabis Business, free and clear of any encumbrances except certain permitted encumbrances (namely the security of the wholly owned subsidiary of SNDL, which was preserved). The Zenabis acquisition consideration was comprised of (i) the extinguishment of the Company’s senior loan. The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any. The fair value of consideration paid was as follows: Final Extinguishment of senior loan 18,215 18,215 The fair value of the assets and liabilities acquired was as follows: Final Cash 2,509 Accounts receivable 888 Biological assets 909 Prepaid expenses and deposits 1,856 Inventory 4,512 Assets held for sale 6,375 Right of use assets 32 Property, plant and equipment 4,658 Accounts payable and accrued liabilities ( 3,437 ) Lease liabilities ( 87 ) 18,215 Assets held for sale are comprised of a processing facility in Stellarton, Nova Scotia, whose primary purpose was the packaging and processing of value added and derivative products for the adult-use cannabis market. These consolidated financial statements incorporate the operations of Zenabis commencing November 1, 2022. During the period November 1, 2022 to December 31, 2022, the Company recorded revenu es of $ 0.4 mi llion and net loss of $ 1.8 million from the Zenabis operations. Had the acquisition closed on January 1, 2022, management estimates that for the period January 1, 2022, to October 31, 2022, revenue would have increased by $ 2.0 million and net loss would have increased by $ 9.0 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022. The Company incurred costs related to the Zenabis acquisition of $ 0.8 million which have been included in transaction costs.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Disclosure of operating segments [abstract]
Segment Information	6. Segment information The Company’s reportable segments are organized by business line, and with the acquisition of Alcanna, are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as “Corporate”. Liquor Retail (1) Cannabis Retail (1) Cannabis (2) Investments (3) Corporate Total As at December 31, 2022 Total assets 351,338 200,393 163,130 825,151 19,338 1,559,350 Year ended December 31, 2022 Net revenue 462,180 205,610 44,407 — — 712,197 Gross margin 106,307 47,334 ( 13,266 ) — — 140,375 Interest and fee revenue — — — 16,739 — 16,739 Investment (loss) income — — — ( 65,164 ) — ( 65,164 ) Share of loss of equity-accounted investees — — — ( 43,002 ) — ( 43,002 ) Depreciation and amortization 17,025 9,920 199 — 13,801 40,945 Income (loss) before income tax 17,726 ( 183,055 ) ( 29,618 ) ( 127,362 ) ( 57,461 ) ( 379,770 ) (1) Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a) ). (2) Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c) ). (3) Total assets include cash and cash equivalents. Liquor Retail Cannabis Retail (1) Cannabis Investments (2) Corporate Total As at December 31, 2021 Total assets (3) — 157,022 147,887 1,093,596 29,155 1,427,660 Year ended December 31, 2021 Net revenue — 16,091 40,037 — — 56,128 Gross margin (3) — 6,498 ( 15,499 ) — — ( 9,001 ) Interest and fee revenue — — — 13,149 — 13,149 Investment loss — — — ( 44,501 ) — ( 44,501 ) Share of profit of equity-accounted investees — — — 32,913 — 32,913 Depreciation and amortization (3) — 1,282 3,108 — 897 5,287 Income (loss) before income tax (3) — ( 410 ) ( 117,990 ) ( 5,837 ) ( 110,461 ) ( 234,698 ) (1) Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021. (2) Total assets include cash and cash equivalents. (3) Adjustments to provisional amounts — refer to note 5(b) Geographical disclosure As at December 31, 2022, the Company had non-current assets related to investment credit operations in the United States of $ 519.3 million (December 31, 2021 — $ 412.9 million ). For the year ended December 31, 2022, share of profit of equity-accounted investees related to investment credit operations in the United States was a loss of $ 43.0 million (year ended December 31, 2021 — gain of $ 32.9 million ).

Restricted Cash

Restricted Cash	12 Months Ended
	Dec. 31, 2022
Restricted Cash [Abstract]
Restricted Cash	7. Restricted cash As at December 31, 2022 December 31, 2021 Securities collateral — 7,773 Captive insurance 19,044 19,240 Other 294 — 19,338 27,013 Securities collateral is comprised of a cash balance to satisfy margin requirements on the Company’s option trading positions. The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures (note 3).

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2022
Marketable Securities Disclosure [Abstract]
Marketable Securities	8. Marketable securities As at December 31, 2022 December 31, 2021 Balance, beginning of year 83,724 — Additions 3,755 158,101 Dispositions — ( 9,663 ) Change in fair value recognized in profit or loss ( 65,553 ) ( 64,714 ) Balance, end of year 21,926 83,724 During the year ended December 31, 2022 , proceeds of nil ( year ended December 31, 2021 — $ 29.9 million ) were received for dispositions of marketable securities and a gain on disposition of nil ( year ended December 31, 2021 — $ 20.2 million ) was recognized (note 26). Marketable securities have been designated as FVTPL (note 31). Subsequent to December 31, 2022, the marketable securities held in Valens were converted to SNDL common shares and subsequently cancelled in relation to the Valens acquisition (note 36). The components of marketable securities are as follows: As at December 31, 2022 December 31, 2021 Equity securities 21,926 83,802 Put and call options — ( 78 ) 21,926 83,724

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Accounts Receivable	9. Accounts receivable As at December 31, 2022 December 31, 2021 Trade receivables 17,558 10,865 Other receivables 5,078 — 22,636 10,865 The Company has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Refer to note 31 for credit risk disclosures.

Biological Assets

Biological Assets	12 Months Ended
	Dec. 31, 2022
Disclosure of reconciliation of changes in biological assets [abstract]
Biological Assets	10. Biological assets The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows: As at December 31, 2022 December 31, 2021 Balance, beginning of year 4,410 3,531 Increase in biological assets due to capitalized costs 27,749 25,880 Acquisition 909 — Net change in fair value of biological assets ( 1,309 ) 4,708 Transferred to inventory upon harvest ( 28,282 ) ( 29,709 ) Balance, end of year 3,477 4,410 Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows: Assumption Input Weighted average input Effect of 10 % change ($000s) December 31 December 31 December 31 December 31 Yield per square foot of growing space (1) Grams 48 49 279 435 Average net selling price (2) $/gram 4.66 4.49 687 1,014 After harvest cost to complete and sell $/gram 1.27 1.06 187 249 (1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available. (2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available. These assumptions are estimates that are subject to volatility in market prices and several uncontrollable factors. The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods. The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2022, it is estimated that the Company’s biological assets will yield approximately 3,904 kilograms (December 31, 2021 – 5,672 kilograms) of dry cannabis when harvested. During the year ended December 31, 2022, the Company harvested 19,854 kilograms of dry cannabis (year ended December 31, 2021 – 22,784 kilograms).

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Classes of current inventories [abstract]
Inventory	11. Inventory As at December 31, 2022 December 31, 2021 Retail liquor 82,589 — Harvested cannabis Raw materials, packaging and components 4,577 4,354 Work-in-progress 19,927 19,751 Finished goods 7,040 2,966 Retail cannabis 13,373 2,397 Millwork 276 35 127,782 29,503 During the year ended December 31, 2022, inventories of $ 558.1 million were recognized in cost of sales as an expense (year ended December 31, 2021 - $ 50.6 million ). During the year ended December 31, 2022, the Company recognized inventory write downs of $ 8.9 million (year ended December 31, 2021 - $ 17.5 million ), of which $ 7.0 million (year ended December 31, 2021 - $ 17.0 million ) was recognized as an impaired and obsolete inventory provision, and $ 1.9 million (year ended December 31, 2021 - $ 0.5 million ) was included in the change in fair value realized through inventory as the fair value component of the impaired and obsolete inventory provision.

Right Of Use Assets

Right Of Use Assets	12 Months Ended
	Dec. 31, 2022
Disclosure of quantitative information about right-of-use assets [abstract]
Right Of Use Assets	12. right of use assets Cost Balance at December 31, 2020 1,894 Acquisition (note 5(b)) 5,730 Additions 579 Dispositions ( 165 ) Balance at December 31, 2021 8,038 Acquisition (note 5(a), note5(c)) 140,781 Additions 6,103 Tenant inducement allowances ( 46 ) Dispositions and remeasurements 12,191 Balance at December 31, 2022 167,067 Accumulated depreciation and impairment Balance at December 31, 2020 571 Depreciation 897 Dispositions ( 147 ) Balance at December 31, 2021 1,321 Depreciation 25,227 Impairment 6,365 Balance at December 31, 2022 32,913 Net book value Balance at December 31, 2021 6,717 Balance at December 31, 2022 134,154 As at December 31, 2022 , the Company recorded impairment losses of right of use assets of $ 6.4 million with $ 3.9 million in the cannabis retail reporting segment and $ 2.5 million in the liquor retail reporting segment. Refer to note 13 for the significant assumptions applied in the impairment test.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Property, Plant and Equipment	13. Property, plant and equipment Land Production facilities Leasehold improvements Equipment Construction Total Cost Balance at December 31, 2020 8,640 152,935 2 28,894 8,819 199,290 Acquisition (note 5(b)) — — 4,169 2,209 — 6,378 Additions — 467 126 1,975 1,209 3,777 Transfers from CIP 3,748 — — — ( 3,748 ) — Dispositions — ( 70 ) ( 398 ) ( 301 ) ( 177 ) ( 946 ) Balance at December 31, 2021 12,388 153,332 3,899 32,777 6,103 208,499 Acquisition (note 5(a), note5(c)) 130 2,982 65,605 44,263 2,369 115,349 Additions 57 256 3,465 5,907 982 10,667 Dispositions ( 611 ) ( 3,844 ) ( 647 ) ( 4,025 ) — ( 9,127 ) Balance at December 31, 2022 11,964 152,726 72,322 78,922 9,454 325,388 Accumulated depreciation and impairment Balance at December 31, 2020 — 69,364 — 8,500 5,821 83,685 Depreciation — 2,503 411 5,438 — 8,352 Impairment — 60,000 — — — 60,000 Dispositions — — — ( 10 ) — ( 10 ) Balance at December 31, 2021 — 131,867 411 13,928 5,821 152,027 Depreciation — 1,288 7,212 11,373 — 19,873 Impairment — — 7,794 7,415 — 15,209 Dispositions — ( 1,324 ) ( 610 ) ( 3,196 ) — ( 5,130 ) Balance at December 31, 2022 — 131,831 14,807 29,520 5,821 181,979 Net book value Balance at December 31, 2021 12,388 21,465 3,488 18,849 282 56,472 Balance at December 31, 2022 11,964 20,895 57,515 49,402 3,633 143,409 During the year ended December 31, 2022, depreciation expense of $ 6.4 million was capitalized to biological assets and inventory (year ended December 31, 2021 – $ 4.9 million ). During the year ended December 31, 2022 , proceeds of $ 3.5 million were received for the disposition of the Company’s Merritt facility and a gain on disposal of $ 0.5 million was recognized. At December 31, 2021, the Merritt facility was classified as assets held for sale. During the year ended December 31, 2022 , proceeds of $ 3.9 million were received for the disposition of the Company’s Rocky View facility and no gain on disposal was recognized. During the year ended December 31, 2022 , the Company determined that indicators of impairment existed relating to idle machinery and equipment. The estimated recoverable amount of the assets was determined to be nil and an impairment of $ 2.4 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment. During the year ended December 31, 2022, the Company determined that indicators of impairment existed relating to its retail stores due to underperforming operating results of certain stores. For impairment testing of retail property, plant and equipment and right of use assets, the Company determined that a CGU was defined as each individual retail store. The Company completed impairment tests for each store location determined to have an indicator of potential impairment using a discounted cash flow methodology. The recoverable amounts for each CGU were based on the higher of its estimated value in use (“VIU”) and fair value less costs of disposal (“FVLCD”) using level 3 inputs (refer to note 31 for further discussion of each input level). The significant assumptions applied in the impairment test are described below: • Cash flows: Estimated cash flows are based on forecasted EBITDA. The forecast is extended to a total of five years based on an analysis of the industry’s expected growth rates, historical and forecast volume changes, and inflation rates, except where a CGU has a defined life due to lease expiration. Management determined forecasted growth rates of sales based on past performance and its expectations of future performance for each location. Expenditures were based upon a combination of historical percentages of revenue, sales growth rates, and contractual lease payments. • Discount rate: The weighted average cost of capital was estimated to be 12.0 % and is based on market capital structure of debt, risk-free rate, equity risk premium, beta adjustment to the equity risk premium based on a review of betas of comparable publicly traded companies, the Company’s historical data, an unsystematic risk premium and after-tax cost of debt based on corporate bond yields. • Long-term growth rate: Five years of cash flows have been included in the discounted cash flow models. Where a CGU’s lease terms do not define the forecast period, maintainable debt-free net cash flow beyond the forecast period is estimated to approximate the fifth-year cash flows increased by a terminal growth rate of 2.5 % and is based on the industry’s expected growth rates, forecast inflation rates and management’s experience. As at December 31, 2022 , the Company recorded impairment losses of property, plant and equipment of $ 12.8 million with $ 5.3 million in the cannabis retail reporting segment and $ 7.5 million in the liquor retail reporting segment. Due to curtailment in the utilization of a portion of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates, the Company determined that indicators of impairment existed at June 30, 2021. The impairment test for the Company’s Olds CGU used a value in use approach based on internal cash flow estimates at June 30, 2021, and a discount rate of 25 %. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5 -year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s Olds CGU of $ 60.0 million as at June 30, 2021, as the estimated recoverable amount for this CGU of $ 70.0 million was lower than the respective carrying amount. The estimated value in use for the Company’s Olds CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1 % would increase the impairment by approximately $ 7.3 million. The impairment was recognized in the Company’s cannabis operations reporting segment.

Net Investment In Subleases

Net Investment In Subleases	12 Months Ended
	Dec. 31, 2022
Disclosure Of Net Investment In Subleases [Abstract]
Disclosure of Net Investment in Subleases Explanatory	14. Net investment in subleases December 31, 2022 December 31, 2021 Balance, beginning of year 26,562 — Acquisition (note 5(b)) — 23,801 Additions 1,408 3,951 Finance income 833 573 Rents recovered (payments made directly to landlords) ( 4,141 ) ( 1,713 ) Dispositions and remeasurements ( 1,343 ) ( 50 ) Balance, end of year 23,319 26,562 Current portion 3,701 3,991 Long-term 19,618 22,571 Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about intangible assets [abstract]
Intangible Assets	15. Intangible assets Brands and trademarks Franchise agreements Software Retail Licenses Total Cost Balance at December 31, 2020 5,445 — — — 5,445 Acquisition (note 5(b)) (1) 36,000 10,000 — — 46,000 Balance at December 31, 2021 41,445 10,000 — — 51,445 Acquisition (note 5(a)) 38,950 — 5,400 750 45,100 Additions 55 — 142 — 197 Dispositions ( 50 ) — — — ( 50 ) Balance at December 31, 2022 80,400 10,000 5,542 750 96,692 Accumulated amortization and impairment Balance at December 31, 2020 382 — — — 382 Amortization (1) 354 561 — — 915 Balance at December 31, 2021 736 561 — — 1,297 Amortization 293 1,250 679 — 2,222 Impairment 18,288 — — — 18,288 Balance at December 31, 2022 19,317 1,811 679 — 21,807 Net book value Balance at December 31, 2021 40,709 9,439 — — 50,148 Balance at December 31, 2022 61,083 8,189 4,863 750 74,885 (1) Adjustment to provisional amounts — refer to note 5(b) . Brands and trademarks are related to intellectual property purchased from Sun 8 Holdings Inc. (“Sun 8”) with a useful life of 15 years, other intellectual property with a useful life of 12 years, intellectual property acquired through the acquisition of Inner Spirit consisting of proprietary rights to brands and trademarks with an indefinite useful life, and intellectual property acquired through the acquisition of Alcanna with an indefinite useful life. The Inner Spirit and Alcanna brands and trademarks were determined to have an indefinite useful life due to the fact that there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Franchise agreements consist of intellectual property acquired through the acquisition of Inner Spirit consisting of franchise relationships with a useful life of 8 years. Software is comprised of licenses acquired through the acquisition of Alcanna and are amortized using the straight-line method over the life of the license. Retail licenses acquired through the acquisition of Alcanna have an indefinite life and are therefore not amortized. The retail licenses do not expire, but rather are subject to an administrative extension process each year indefinitely. During the three months ended September 30, 2022, the Company determined that indicators of impairment existed regarding the Sun 8 intellectual property due to decreasing market competition. The estimated recoverable amount of the intangible asset was determined to be $ 2.5 million and an impairment of $ 1.9 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment. At September 30, 2022, the Company recorded impairments to intangible assets with indefinite useful lives of $ 16.4 million due to changes in circumstances since the date of the Inner Spirit acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(b)). At December 31, 2022, the Company tested intangible assets with indefinite useful lives and goodwill for impairment based on changes in circumstances since the date of the Alcanna and Nova acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(a) ).

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Disclosure Of Investments [Abstract]
Investments	16. Investments As at December 31, 2022 December 31, 2021 Investments at amortized cost 24,493 24,987 Investments at FVTPL 72,761 48,576 97,254 73,563 Current portion 6,552 3,065 Long-term 90,702 70,498 Investments at fvtpl Superette On February 9, 2022, the Company closed an investment in a $ 5.0 million promissory note with a maturity date of February 9, 2025 , and an interest rate of 15 % per annum. On August 26, 2022, November 22, 2022 and December 31, 2022, the Company entered into an amended and restated promissory note whereby the Company would advance additional funds up to $ 8.1 million as part of pre-CCAA advances and debtor-in-possession advances and the maturity date was amended such that the full balance of the promissory note plus accrued interest and advances became due August 30, 2022. On August 31, 2022, the Company announced that, in the context of the initial order obtained by Superette Inc., Superette Ontario Inc. and certain of its subsidiaries (collectively, “Superette”) from the Ontario Superior Court of Justice on August 30, 2022 pursuant to the CCAA proceedings, it had entered into an agreement of purchase and sale with Superette, pursuant to which it proposed to acquire substantially all of the business and assets of Superette. As at December 31, 2022, the Company had advanced an additional $ 1.8 million under the amended and restated promissory note. Subsequent to December 31, 2022, the Company had advanced an additional $ 0.3 million under the amended and restated promissory note. The Company has adjusted the fair value of the promissory note downward by $ 3.7 million during the year ended December 31, 2022 (note 28) to management’s best estimate of the recoverable value of the collateral underlying the security of the promissory note. On February 7, 2023, the Company announced the acquisition of Superette (note 36). Delta 9 On March 30, 2022, the Company closed an investment in a $ 10.0 million convertible debenture with Delta 9 Cannabis Inc. with a maturity date of March 30, 2025 , and an interest rate of 10 % per annum. On August 11, 2022, and again on September 9, 2022, the Company waived compliance under certain covenants in exchange for a requirement to meet additional conditions. Zenabis On June 17, 2022, Zenabis Global Inc. (“Zenabis Global”), as well as Zenabis Global’s direct and indirect wholly owned subsidiaries (collectively, the “Zenabis Global Group”), filed a petition with the Québec Superior Court for protection under CCAA. On June 16, 2022 (and amended on July 5, 2022), the Company entered into a purchase agreement pursuant to which the shares of Zenabis Global and all business and assets of the Zenabis Global Group (the “Zenabis Business”) would be acquired by SNDL. On November 1, 2022, the Company announced the acquisition of certain assets and permitted liabilities of Zenabis Global (note 5(c) ). The Company has adjusted the fair value of the Zenabis Global senior loan downward by $ 33.7 million (note 28) to management’s best estimate of the fair value of the Zenabis Global senior loan at November 1, 2022, in accordance with the requirements of IFRS. The Zenabis Global senior loan was extinguished immediately preceding the business combination and forms the consideration transferred (note 5(c)). Valens On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) to combine their businesses. Pursuant to the terms of the Valens Arrangement Agreement, the Company will acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). In connection with the Valens Arrangement Agreement, the Company and Valens closed a $ 60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10 % per annum. T he Valens Transaction closed on January 17, 2023 (note 36 ).

Equity-Accounted Investees

Equity-Accounted Investees	12 Months Ended
	Dec. 31, 2022
Disclosure Of Interests In Other Entities [Abstract]
Equity-Accounted Investees	17. Equity-accounted investees As at December 31, 2022 December 31, 2021 Interest in joint venture (A) 519,255 412,858 Interest in associate (B) — — 519,255 412,858 a) Interest in joint venture SunStream is a joint venture in which the Company has a 50 % ownership interest. SunStream is a private company, incorporated under the Business Corporations Act (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. SunStream is structured as a separate vehicle and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method. The current investment portfolio of SunStream is comprised of secured debt, hybrid debt and derivative instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risk and other risks specific to each investment. As at December 31, 2022, the Company had funded $ 514.7 million out of the total $ 538.0 million that was originally committed to SunStream . Subsequent to December 31, 2022 , the Company contributed $ 10.9 million to SunStream. The following table summarizes the carrying amount of the Company’s interest in the joint venture: Carrying amount Balance at December 31, 2020 — Capital contributions 395,569 Share of net earnings 32,913 Share of other comprehensive income 9,878 Distributions ( 25,502 ) Balance at December 31, 2021 412,858 Capital contributions 119,137 Share of net earnings (loss) ( 43,002 ) Share of other comprehensive income 31,923 Distributions ( 1,661 ) Balance at December 31, 2022 519,255 SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions. The following table summarizes the financial information of SunStream: As at December 31, 2022 December 31, 2021 Current assets (including cash and cash equivalents - 2022: $ 1.5 million, 2021: $ 0.2 million) 5,437 789 Non-current assets 509,418 407,860 Current liabilities ( 1,146 ) ( 1,596 ) Net assets (liabilities) ( 100 %) 513,709 407,053 Year ended December 31 2022 2021 Revenue (loss) ( 35,046 ) 36,203 Profit (loss) from operations ( 42,627 ) 32,841 Other comprehensive income 31,923 9,878 Total comprehensive income (loss) ( 10,619 ) 42,747 b) Interest in associate The Company holds a 25 % equity interest in its associate Pathway RX Inc. (“Pathway”). Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a range of medical cannabis. The carrying amount of the Company’s interest in Pathway is nil.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Accounts Payable and Accrued Liabilities	18. Accounts payable and accrued liabilities December 31, 2022 December 31, 2021 Trade payables 9,774 4,172 Accrued and other liabilities 38,379 34,280 48,153 38,452

Derivative Warrants

Derivative Warrants	12 Months Ended
	Dec. 31, 2022
Derivative Warrant Liabilities [Abstract]
Derivative Warrants	19. Derivative warrants December 31, 2022 December 31, 2021 Balance, beginning of year 21,700 428 2021 Series A and B Warrants - fair value on issuance — 62,680 2021 Additional Series A and B Warrants - fair value on issuance — 38,576 New Warrants - fair value on issuance recognized in profit or loss — 106,531 Change in fair value recognized in profit or loss ( 10,783 ) ( 28,697 ) Converted to common shares — ( 157,818 ) Acquisition (note 5(a)) 85 — Balance, end of year 11,002 21,700 The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised. The following table summarizes outstanding derivative warrants as at December 31, 2022: Exercise price (USD) Number of warrants Weighted average contractual life 2020 Series A Warrants (1) 1.77 50,000 2.6 Unsecured Convertible Notes Warrants (1) 1.77 50,000 1.0 New Warrants (2) 2.29 9,833,333 1.6 December 2018 Performance Warrants CAD 5.51 118,067 1.0 10,051,400 1.6 (1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable. (2) The exercise price of the New Warrants was adjusted from USD $ 15.00 to $ 2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a) ). In connection with the Alcanna Transaction (note 5(a)), the Company acquired warrants previously issued by Nova (the “December 2018 Performance Warrants”) that are classified as a liability. The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $ 19.27 at any time prior to the expiration date of the warrants. The Market Price condition has not been met. As such, the fair value of the December 2018 Performance Warrants was recognized as a warrant liability, inclusive of a probability weighting associated with the performance incentive being met. Under the terms of the warrant agreements, each performance warrant can be exercised for 0.05449 to 0.08174 of a Nova common share (depending on whether pe rformance conditions are met) prior to the expiration date of December 18, 2023, at an exercise price of $ 5.51 per Nova common share. At December 31, 2022 , there were 118,067 December 2018 Performance Warrants outstanding.

Lease Liabilities

Lease Liabilities	12 Months Ended
	Dec. 31, 2022
Lease liabilities [abstract]
Lease Liabilities	20. Lease LIABILITIES December 31, 2022 December 31, 2021 Balance, beginning of year 33,470 1,440 Acquisition (note 5(a), note5(c)) 142,106 29,531 Additions 7,497 4,514 Lease payments ( 31,834 ) ( 2,721 ) Dispositions and remeasurements 10,890 ( 70 ) Tenant inducement allowances received 1,799 — Accretion expense 5,903 776 Balance, end of year 169,831 33,470 Current portion 30,206 5,701 Long-term 139,625 27,769 The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company’s lease liabilities as at December 31, 2022: December 31, 2022 Less than one year 39,255 One to three years 64,892 Three to five years 48,955 Thereafter 47,468 Minimum lease payments 200,570 The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2022 and 2021.

Other Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2022
Disclosure Of Other Liabilities [Abstract]
Other Liabilities	21. Other liabilities December 31, 2022 December 31, 2021 Financial guarantee liability (A) 407 466 Deferred share units liability (B) 2,302 4,039 2,709 4,505 a) Financial guarantee liability For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of ECLs in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs (note 28) in the consolidated statement of loss and comprehensive loss. b) DSU liability Deferred share units (“DSUs”) are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder, equal to the fair value of the Company’s common shares calculated at the date of such payment, when a director leaves the board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. Changes in the fair value are recognized within share-based compensation expense (note 24(d) ).

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Major components of tax expense (income) [abstract]
Income Taxes	22. Income taxes The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in profit and loss for the years ended December 31, 2022, December 31, 2021 and December 31, 2020: December 31, 2022 December 31, 2021 December 31, 2020 Loss before taxes ( 379,770 ) ( 234,698 ) ( 206,317 ) Statutory income tax rates 23.0 % 23.0 % 24.0 % Expected income tax recovery ( 87,347 ) ( 53,981 ) ( 49,516 ) Non-deductible share-based compensation 2,508 2,308 1,970 Non-deductible finance expense — 2 2,130 Revaluation of the fair value of warrant liabilities ( 2,461 ) 17,902 — Non-controlling interest 8,167 — — Non-deductible portion of capital losses 7,458 5,118 — Other non-deductible expenses 5,409 610 348 Goodwill impairment 35,919 — — Change in tax rates — — 1,528 Deferred tax benefits not recognized 23,005 20,127 43,540 Income tax (recovery) expense ( 7,342 ) ( 7,914 ) — Details of the deferred tax assets (liabilities) are as follows: December 31, 2022 December 31, 2021 Deferred tax assets (liabilities): Inventory 23,329 20,472 Biological assets ( 9,451 ) ( 9,509 ) Net investment in subleases ( 5,363 ) ( 6,119 ) Intangible assets ( 16,632 ) — Lease liabilities ( 5,488 ) ( 8,361 ) Marketable securities 14,981 7,442 Equity-accounted investee ( 1,376 ) ( 3,925 ) Net deferred tax asset (liability) — — Deferred tax assets have not been recognized for the following deductible temporary differences: December 31, 2022 December 31, 2021 Unrecognized deductible temporary differences: Property, plant and equipment 7,413 81,583 Intangible assets 183 ( 45,256 ) Share issue costs 28,926 23,835 Investments 18,239 3,300 Lease liabilities 193,691 69,865 Financial obligations and other 2,300 4,100 Non-capital losses & scientific research and experimental development 490,326 220,596 Unrecognized deductible temporary differences 741,078 358,023 The movement in deferred income tax liability is as follows: December 31, 2022 December 31, 2021 Balance, beginning of year — — Recognized in profit and loss ( 7,342 ) ( 7,914 ) Recognized in other comprehensive income 7,342 7,914 Balance, end of year — — The Company has $ 490.3 million (December 31, 2021 - $ 218.5 million) of non-capital losses available for future periods that will expire prior to 2037-2042.

Share Capital and Warrants

Share Capital and Warrants	12 Months Ended
	Dec. 31, 2022
Share Capital And Warrants [Abstract]
Share Capital and Warrants	23. Share capital and warrants a) Authorized The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value. On July 26, 2022, the Board approved a 1 to 10 share consolidation of the Company’s issued and outstanding common shares (the “Share Consolidation”). Each shareholder of record of the Company as of the close of business on the record date of July 25, 2022, received 1 common share for each 10 shares held on such date. All references to common shares, warrants, derivative warrant liabilities, simple warrants, performance warrants, stock options, RSUs and DSUs (excluding the Nova RSUs and DSUs) have been fully retrospectively adjusted to reflect the Share Consolidation. b) Issued and outstanding December 31, 2022 December 31, 2021 Note Number of Carrying Number of Carrying Balance, beginning of year 206,040,836 2,035,704 91,884,413 762,046 Share issuances 370,179 2,870 95,680,666 977,425 Share issuance costs — — — ( 16,371 ) Share repurchases ( 4,252,489 ) ( 41,617 ) — — Acquisition 5 32,060,135 287,129 2,443,128 26,216 Convertible debenture settlement — — 248,875 2,671 Derivative warrants exercised — — 15,214,695 277,136 Warrants exercised — — 19,571 178 Employee awards exercised (1) 975,575 8,724 549,488 6,403 Balance, end of year 235,194,236 2,292,810 206,040,836 2,035,704 (1) Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022. For the year ended December 31, 2022, the Company purchased and cancelled 4.3 million c ommon shares at a weighted average price of $ 3.12 (US$ 2.33 ) per common share for a total cost of $ 13.3 million. Accumulated deficit was reduced by $ 28.3 million, representing the excess of the average carrying value of the common shares over their purchase price. Subsequent to December 31, 2022 , the Company purchased and cancelled 0.5 million common shares at a weighted average pric e of $ 2.78 (US$ 2.04 ) per common share for a total cost of $ 1.5 million. (C) Common share purchase warrants Number of Warrants Carrying Amount Balance at December 31, 2020 102,400 6,138 Acquisition (note 5(b)) 209,783 1,771 Warrants issued 64,000 361 Warrants exercised ( 19,571 ) ( 178 ) Balance at December 31, 2021 356,612 8,092 Warrants expired ( 48,000 ) ( 5,832 ) Balance at December 31, 2022 308,612 2,260 During the year ended December 31, 2022, the warrants issued in relation to the acquisition of a financial obligation expired. During the year ended December 31, 2021, the Company issued 64,000 warrants to Sun 8 Holdings Inc. (“Sun 8”) with an exercise price of $ 9.40 per unit, in conjunction with achieving minimum thresholds of revenue derived from the brands or cultivars that the Company acquired from Sun 8 during the year ended December 31, 2019. During the year ended December 31, 2021, 19,571 warrants that formed part of the contingent consideration from the Inner Spirit Transaction, were exercised resulting in a net payment of $ 0.2 million representing the difference between the exercise prices and the cash consideration (note 5(b)). The carrying value of the exercised warrants was adjusted from warrants to share capital. The following table summarizes outstanding warrants as at December 31, 2022: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average Financial services 45.98 54,400 6.6 Acquired from Inner Spirit (1) 3.37 190,212 1.2 Sun 8 9.40 64,000 3.0 $ 12.13 308,612 2.5 (1) Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b) ) and have been presented based on the number of SNDL common shares that are issuable.

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-based Compensation	24. Share-based compensation The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, RSUs and DSUs. Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants. The components of share-based compensation expense are as follows: Year ended 2022 2021 2020 Equity-settled expense Simple warrants (A) 1,299 2,899 1,539 Performance warrants (A) — 361 ( 42 ) Stock options (B) 78 ( 14 ) 651 Restricted share units (1) (C) 9,423 6,789 4,069 Cash-settled expense Deferred share units (1)(2) (D) ( 1,129 ) 2,272 2,349 9,671 12,307 8,566 (1) For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $ 107 and share-based compensation expense under Nova’s DSU plan of $ 404 . (2) Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur. Equity-settled plans a) Simple and performance warrants The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants expire five years after vesting criteria met. The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2022 and the year ended December 31, 2021: Simple Weighted Performance Weighted Balance at December 31, 2020 342,460 $ 44.13 167,200 $ 41.89 Forfeited ( 66,880 ) 33.62 ( 20,480 ) 54.80 Exercised ( 12,000 ) 9.38 ( 8,000 ) 10.94 Expired ( 4,160 ) 34.51 — 0.00 Balance at December 31, 2021 259,420 $ 48.60 138,720 $ 41.77 Forfeited ( 82,400 ) 57.77 ( 15,520 ) 37.86 Expired ( 11,200 ) 6.25 — 0.00 Balance at December 31, 2022 165,820 $ 46.91 123,200 $ 42.26 The following table summarizes outstanding simple and performance warrants as at December 31, 2022: Warrants outstanding Warrants exercisable Range of exercise prices Number of Weighted Weighted Number of Weighted Weighted Simple warrants $6.25 - $9.38 75,340 7.25 1.40 75,340 7.25 1.40 $29.69 - $45.31 27,120 31.26 1.61 26,320 31.02 1.54 $62.50 - $93.75 49,920 63.50 4.05 49,920 63.50 4.05 $125.00 - $375.00 13,440 239.15 4.62 7,040 205.18 3.70 165,820 $ 46.91 2.49 158,620 $ 37.68 2.36 Performance warrants $6.25 - $9.38 45,066 6.71 n/a 45,066 6.71 2.00 $12.50 - $18.75 17,334 15.15 n/a 17,334 15.15 0.93 $29.69 - $45.31 42,400 31.99 n/a 42,400 31.99 1.22 $62.50 - $93.75 9,334 77.68 n/a 1,334 93.75 1.10 $125.00 - $375.00 9,066 282.36 n/a — — n/a 123,200 $ 42.26 n/a 106,134 $ 19.28 1.91 b) Stock options The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and generally expire ten years after the grant date. The following table summarizes changes in stock options during the year ended December 31, 2022 and the year ended December 31, 2021: Stock options outstanding Weighted Balance at December 31, 2020 72,060 $ 18.18 Forfeited ( 27,500 ) 26.05 Expired ( 100 ) 31.50 Balance at December 31, 2021 44,460 $ 13.28 Expired ( 100 ) 31.50 Balance at December 31, 2022 44,360 $ 13.24 The following table summarizes outstanding stock options as at December 31, 2022: Stock options outstanding Stock options exercisable Exercise prices Number of Weighted Number of Weighted $11.50 32,500 7.41 21,667 7.41 $11.90 8,160 7.49 8,160 7.49 $31.50 3,700 5.51 3,025 5.38 44,360 7.27 32,852 7.24 c) Restricted share units RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares. The following table summarizes changes in RSUs during the year ended December 31, 2022 and the year ended December 31, 2021: RSUs Balance at December 31, 2020 165,692 Granted 1,238,152 Forfeited ( 158,263 ) Exercised ( 491,988 ) Balance at December 31, 2021 753,593 Granted 1,728,557 Forfeited ( 175,245 ) Exercised ( 925,575 ) Balance at December 31, 2022 1,381,330 Subsequent to December 31, 2022 , the Company granted 7.8 million RSUs to employees as part of its long-term incentive program. Cash-settled plans d) Deferred share units DSUs are granted to directors and generally vest in equal instalments over one year . DSUs are settled by making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. As at December 31, 2022, the Company recognized a liability of $ 2.3 million relating to the fair value of cash-settled DSUs (December 31, 2021 – $ 4.0 million). The liability is included as a non-current liability within other liabilities (note 21). The following table summarizes changes in DSUs during the year ended December 31, 2022 and the year ended December 31, 2021: DSUs Balance at December 31, 2020 332,331 Granted 248,919 Exercised ( 30,000 ) Balance at December 31, 2021 551,250 Granted 1,216,076 Exercised ( 58,943 ) Balance at December 31, 2022 1,708,383 As at December 31, 2022 , nil ( December 31, 2021 – 0.6 million) DSUs were exercisable.

Gross Revenue

Gross Revenue	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Gross Revenue	25. Gross revenue Liquor retail revenue is derived from the sale of wines, beers and spirits to customers. Cannabis retail revenue is derived from retail cannabis sales to customers, franchise revenue consists of royalty, advertising and franchise fee revenue, and other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers. Year ended 2022 2021 2020 Liquor retail revenue 462,180 — — Cannabis retail revenue Retail 192,710 10,207 — Franchise 8,337 4,251 — Other 4,563 1,633 — Cannabis retail revenue 205,610 16,091 — Cannabis revenue Provincial boards 58,728 41,338 55,315 Medical 9 8 32 Wholesale 3,167 9,842 17,974 Cannabis revenue 61,904 51,188 73,321 Gross revenue 729,694 67,279 73,321 The Company has recognized the following receivables from contracts with customers: December 31, 2022 December 31, 2021 December 31, 2020 Receivables, included in 'trade receivables' (note 9) 17,558 10,865 15,786 Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2022, an impairment of $ 0.6 million (December 31, 2021 – $ 0.2 million) has been recognized on receivables from contracts with customers (note 31 ).

Investment Revenue (Loss)

Investment Revenue (Loss)	12 Months Ended
	Dec. 31, 2022
Investment Revenue (Loss) [Abstract]
Investment Revenue (Loss)	26. Investment revenue (Loss) Year ended 2022 2021 2020 Interest and fee revenue Interest revenue from investments at amortized cost 3,660 1,654 — Interest and fee revenue from investments at FVTPL 6,036 8,514 — Interest revenue from cash 7,043 2,981 — 16,739 13,149 — Year ended 2022 2021 2020 Investment loss Realized gains 389 20,213 — Unrealized (losses) gains (note 8) ( 65,553 ) ( 64,714 ) — ( 65,164 ) ( 44,501 ) —

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Dec. 31, 2022
Expenses by nature [abstract]
Other Operating Expenses	27. Other operating expenses a) General and administrative Year ended 2022 2021 (1) 2020 Salaries and wages 80,134 18,675 11,634 Consulting fees 1,934 1,112 2,193 Office and general 37,061 7,560 9,843 Professional fees 11,563 6,530 4,658 Merchant processing fees 4,748 — — Director fees 472 351 365 Other 4,256 3,815 3,336 140,168 38,043 32,029 (1) Adjustment to provisional amounts — refer to note 5(b) . b) Sales and marketing Year ended 2022 2021 2020 Marketing 7,308 3,671 4,839 Events 102 191 393 Research — 43 57 Media 1,007 1,138 448 8,417 5,043 5,737

Finance Costs

Finance Costs	12 Months Ended
	Dec. 31, 2022
Disclosure Of Finance Cost [Abstract]
Finance Costs	28. Finance costs Year ended 2022 2021 2020 Cash finance expense Interest on long-term debt — — 7,482 Other finance costs 178 40 286 178 40 7,768 Non-cash finance expense (income) Change in fair value of investments at FVTPL 36,087 3,300 — Accretion on lease liabilities 5,903 776 89 Financial guarantee liability (recovery) expense ( 59 ) 59 — Accretion — — 1,622 Amortization of debt issue costs — — 1,782 Change in fair value of convertible notes — — ( 7,141 ) Other 89 154 ( 86 ) 42,020 4,289 ( 3,734 ) Interest income ( 884 ) ( 573 ) ( 215 ) 41,314 3,756 3,819

Supplemental Cash Flow Disclosu

Supplemental Cash Flow Disclosures	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Disclosure [Abstract]
Supplemental Cash Flow Disclosures	29. Supplemental cash flow disclosures Year ended 2022 2021 2020 Cash provided by (used in): Accounts receivable ( 5,815 ) 9,339 ( 2,037 ) Biological assets 533 3,829 13,789 Inventory 4,243 ( 18,318 ) ( 12,315 ) Prepaid expenses and deposits 5,782 ( 3,922 ) 2,280 Investments 918 ( 402 ) — Right of use assets ( 17,510 ) — — Property, plant and equipment 38 ( 305 ) — Accounts payable and accrued liabilities ( 27,864 ) 9,665 ( 20,793 ) Lease liabilities 19,296 — — ( 20,379 ) ( 114 ) ( 19,076 ) Changes in non-cash working capital relating to: Operating ( 22,073 ) 150 ( 5,259 ) Investing 74 ( 612 ) ( 11,319 ) Financing 1,620 348 ( 2,498 ) ( 20,379 ) ( 114 ) ( 19,076 ) Cash interest paid — — 6,094

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
Loss Per Share	30. Loss per share Year ended 2022 2021 2020 Weighted average shares outstanding (000s) Basic and diluted (1) 229,871 186,038 21,865 Continuing operations Net loss attributable to owners of the Company ( 335,114 ) ( 226,984 ) ( 199,619 ) Per share - basic and diluted $ ( 1.46 ) $ ( 1.22 ) $ ( 9.13 ) Discontinued operations Net loss attributable to owners of the Company — — ( 33,627 ) Per share - basic and diluted $ — $ — $ ( 1.54 ) Net loss attributable to owners of the Company ( 335,114 ) ( 226,984 ) ( 233,246 ) Per share - basic and diluted $ ( 1.46 ) $ ( 1.22 ) $ ( 10.67 ) (1) For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs t hat were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	31. Financial instruments The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVTPL, accounts payable and accrued liabilities and derivative warrants. a) Fair value The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions. Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows: Fair value measurements using December 31, 2022 Carrying Level 1 Level 2 Level 3 Recurring measurements: Financial assets Marketable securities 21,926 21,926 — — Investments at FVTPL 72,761 — — 72,761 Financial liabilities Derivative warrants (1) 11,002 — — 11,002 Fair value measurements using December 31, 2021 Carrying Level 1 Level 2 Level 3 Recurring measurements: Financial assets Marketable securities 83,724 83,724 — — Investments at FVTPL 48,576 — — 48,576 Financial liabilities Derivative warrants (1) 21,700 — — 21,700 (1) The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised. Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Marketable securities are designated as FVTPL. The fair value of marketable securities is re-measured each reporting period with changes in fair value recognized in profit and loss. The fair value of marketable securities is estimated by using current quoted prices in active markets for identical assets. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at December 31, 2022, the Company did not have any financial instruments measured at Level 2 fair value. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Investments designated as FVTPL are re-measured each reporting period with changes in the fair value recognized in profit and loss within finance costs. The fair values of the investments were estimated by using a discounted cash flow analysis. The main assumptions used in the calculation were the determination of a credit-adjusted discount rate. Derivative warrants are designated as FVTPL. The fair value of derivative warrants is re-measured each reporting period with changes in fair value recognized in profit and loss within finance costs. The fair value of derivative warrants is estimated by using a valuation model. Assumptions used in these calculations include volatility, discount rate and various probability factors. At December 31, 2022 , a 10 % change in the material assumptions would change the estimated fair value of derivative warrant liabilities by approximately $ 1.3 million. There were no transfers between Levels 1, 2 and 3 inputs during the year. b) Credit risk management Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company. The Company applies the simplified approach under IFRS 9 to accounts receivable and has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Impairment losses on accounts receivable recognized in profit or loss were as follows: As at December 31, 2022 December 31, 2021 Impairment loss (reversal) on trade receivables 642 214 Impairment loss (reversal) on other receivables 674 798 1,316 1,012 The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2022 was as follows: December 31, 2022 December 31, 2021 Balance, beginning of year 1,132 120 Net remeasurement of impairment loss allowance 1,316 1,012 Balance, end of year 2,448 1,132 The Company applies the general approach under IFRS 9 to investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition. The general approach compares the risk of a default occurring at the reporting date with the risk of a default occurring at the date of initial recognition. The Company has evaluated the credit risk of its investments, taking into consideration the risk of default, historical credit loss experience, financial factors specific to the debtors and general economic conditions and determined the expected credit loss to be $ 0.5 million for the year ended December 31, 2022. The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments. c) Market risk management Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities and put and call options. At December 31, 2022 , a 10 % change in the market prices would change the fair value of marketable securities by approximately $ 2.1 million. The Company had no risk management contracts relating to marketable securities outstanding as at December 31, 2022. d) Liquidity risk management Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary. The timing of expected cash outflows relating to financial liabilities at December 31, 2022 is as follows: Less than One to three Three to five Thereafter Total Accounts payable and accrued liabilities 48,153 — — — 48,153 Financial guarantee liability (note 21) — 407 — — 407 Balance, end of year 48,153 407 — — 48,560

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related party transactions [abstract]
Related Party Transactions	32. Related party transactions The Company entered into the following related party transactions during the periods noted, in addition to those disclosed in note 17 relating to the Company’s joint venture. A member of key management personnel jointly controls a company that owns property leased to SNDL for one of its retail liquor stores. The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037. Monthly rent for the location includes base rent, common area costs and sign rent. The rent amounts are subject to increases in accordance with the executed lease agreement. Subsequent to the Alcanna Transaction and for the period March 31, 2022 to December 31, 2022, the Company paid $ 117.9 thousand in total rent with respect to this lease. Compensation of key management personnel The Company considers directors and officers of the Company as key management personnel. Year ended 2022 2021 2020 Salaries and short-term benefits 4,505 2,348 1,944 Share-based compensation 5,871 8,275 7,629 10,376 10,623 9,573

Capital Management

Capital Management	12 Months Ended
	Dec. 31, 2022
Disclosure of objectives, policies and processes for managing capital [abstract]
Capital Management	33. Capital management The Company defines capital as shareholders’ equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to: • Maintain financial flexibility in order to preserve the ability to meet financial obligations; • Deploy capital to provide an appropriate investment return to shareholders; and • Maintain a capital structure that allows various financing alternatives.

Non-Controlling Interests

Non-Controlling Interests	12 Months Ended
	Dec. 31, 2022
Disclosure of Non Controlling Interests [Abstract]
Non-Controlling Interests	34. Non-controlling interests The following tables provide summarized financial information for the Company’s subsidiary, Nova, that has a material non-controlling interest effective the date of closing of the Alcanna Transaction, before inter-company eliminations. The Company does have subsidiaries with non-material non-controlling interests that are not presented in the following financial information. a) Nova summarized statement of financial position 2022 Current assets 18,732 Current liabilities 19,892 Current net assets ( 1,160 ) Non-current assets 94,419 Non-current liabilities 45,443 Non-current net assets 48,976 Net assets 47,816 b) Nova summarized statement of loss and comprehensive loss 2022 Revenue 176,588 Loss and comprehensive loss ( 7,672 ) c) Nova summarized statement of cash flows 2022 Net cash provided by operating activities 5,848 Net cash used in investing activities ( 5,549 ) Net cash used in financing activities ( 183 ) Increase in cash 116

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and contingencies	35. Commitments and contingencies a) Commitments The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2022 of $ 2.5 million ( December 31, 2021 - $ 2.5 million). b) Contingencies From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, franchise partners, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have an adverse impact on our business and results of operations. In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re SNDL Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re SNDL Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions asserted claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally alleged that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also included allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York. In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021. On October 5, 2022, the court entered an order and final judgement approving the settlement. In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. SNDL Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserted claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Exchange Act, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleged that the Company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events	36. Subsequent events Valens Acquisition On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) pursuant to which the Company would acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). Concurrently with the execution of the Valens Arrangement Agreement, the Company assumed Valens’ non-revolving term loan facility from its then-existing lender, and amended and restated the related credit agreement to provide for a $ 60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10 % per annum (the “Valens Facility”). As Valens is now a wholly-owned subsidiary of the Company, the Valens Facility became inter-company debt following the closing of the Valens Transaction. The Valens Transaction closed on January 17, 2023. The Valens Transaction consideration was comprised of (i) the assumption of Valens’ $ 60 million non-revolving term loan facility from its then existing lender, as described above, and (ii) an aggregate 27.6 million SNDL common shares valued at $ 84.0 million based on the fair value of each common share of the Company on the closing date ( 0.3334 of a SNDL common share for each Valens common share). Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments. Valens also distributes medicinal cannabis products to Australia through its subsidiary Valens Australia Pty Ltd. (“Valens Australia”). Additionally, Valens manufactured, distributed, and sold a wide range of CBD products in the United States through its subsidiary Green Roads, Inc. (“Green Roads”), prior to the Valens Transaction. Green Roads filed for bankruptcy in the United States on March 6, 2023. The Company has provided a superpriority secured debtor-in-possession line of credit to Green Roads in the amount of USD $ 1.75 million. Due to the proximity of the closing of the Valens Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. Superette Acquisition On February 7, 2023, the Company announced that, in the context of the Superette Group’s (as defined below) proceedings under the CCAA, it had successfully closed the Superette Transaction (as defined below) contemplated by the agreement of purchase and sale dated August 29, 2022 (as amended and restated on December 12, 2022) (the “APS”) and the approval and vesting order issued by the Ontario Superior Court of Justice (Commercial List) on December 20, 2022. The Superette Group sells cannabis and non-cannabis branded merchandise and has furthered its market exposure and brand awareness through private-label cannabis offerings. Pursuant to the APS, certain of the Superette entities, including Superette Inc. and Superette Ontario Inc. (“Superette Ontario”) (collectively, the “Superette Group”), have sold their right, title and interest in (i) the five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the “Superette IP”); and (iii) the shares of Superette Ontario (collectively, the “Superette Transaction”). Pursuant to applicable laws and regulatory considerations, SNDL directed that the shares of Superette Ontario be transferred to Spirit Leaf Ontario Inc. (“SLO”). SNDL has entered into an option agreement with SLO to purchase all of the issued and outstanding shares of Superette Ontario if certain conditions are met, including compliance with regulatory considerations. The retail location s and intellectual property were transferred to Superette Ontario to assist in operating the retail locations and the Superette IP was transferred to SNDL directly. Certain of the Superette IP will be licensed by SNDL to SLO to allow it to use the Superette brand in the retail locations. Due to the proximity of the closing of the Superette Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. LIGHTBOX Acquisition On March 28, 2023, the Company announced that it had entered into an agreement (the “Lightbox Agreement”) with Lightbox Enterprises Ltd. (“Lightbox”) to acquire four cannabis retail stores operating under the Dutch Love Cannabis banner (“Dutch Love”). Under the Lightbox Agreement, SNDL will acquire from Lightbox the rights to four Dutch Love stores and the rights to use certain Dutch Love related intellectual property for total consideration of $ 7.8 million. The consideration is comprised of i) $ 1.5 million cash; ii) the cancellation of the $ 3.0 million debt owed by Lightbox to SNDL; and iii) $ 3.3 million payable in common shares of SNDL. The transaction is expected to be completed in the context of Lightbox's proceedings under the CCAA from the Supreme Court of British Columbia (the “BC Court”). On December 2, 2022, the BC Court granted an order that approved a sale and investment solicitation process (“SISP”) in respect of the assets, undertakings and properties of Lightbox, and the Agreement is the result of the SISP process. The transaction is anticipated to close by the end of May 2023.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Significant Accounting Policies [Abstract]
Cash and cash equivalents	CASH AND CASH EQUIVALENTS Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.
Restricted cash	RESTRICTED CASH Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading positions, if any, and (ii) minimum funding requirements for two separate captive insurance structures.
Biological assets	BIOLOGICAL ASSETS The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour-related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture (“IAS 41”) and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.
Inventory	INVENTORY Harvested cannabis Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour-related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. Retail inventory Retail inventory at Company-owned stores is valued at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined using the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.
Property, plant, and equipment	PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized. Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates. Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in profit and loss. PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained, if required for operation. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below: • Production facilities — 20 years • Equipment — 1 to 10 years • Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term
Intangible assets	INTANGIBLE ASSETS Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with International Accounting Standard 38 – Intangible Assets (“IAS 38”). The Company’s intangible assets are comprised of the following: • Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years. • Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years. • Intellectual property acquired through the acquisition of Inner Spirit (as defined below) consisting of a trade name with an indefinite life and franchise agreements with useful lives of 8 years. • Intangible assets acquired through the acquisition of Alcanna consisting of brands, licenses, permits and software.
Joint arrangements	Joint arrangements Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets. For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases. Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.
Interests in equity-accounted investees	Interests in equity-accounted investees The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture. Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities. Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.
Impairment of assets	IMPAIRMENT OF ASSETS Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining and maintaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates. (i) Financial assets The Company applies an expected credit loss (“ECL”) model to all financial assets not held at fair value through profit and loss (“FVTPL”) where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under International Financial Reporting Standard 9 – Financial Instruments (“IFRS 9”) and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECLs are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information. (ii) Non-financial assets The carrying amounts of the Company’s PP&E, right of use assets and intangible assets, including goodwill, are assessed for impairment indicators and impairment reversal indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment or impairment reversal. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss or impairment reversal, if any. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of asset’s estimated fair value less costs of disposal and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit (“CGU”)). Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset or CGU is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized previously. A reversal of an impairment loss, net of any depreciation that would have been recorded, is recognized immediately in the statements of loss and comprehensive loss. Impairments of goodwill are not reversed.
Financial instruments	FINANCIAL INSTRUMENTS The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments: Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance. (i) Financial assets At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or fair value through other comprehensive income (“FVOCI”) depending on the business model and contractual cash flows of the instrument. Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss. The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at FVOCI. (ii) Financial liabilities Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss. Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt. The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.
Provisions	Provisions A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2022 and 2021.
Non-monetary transactions	NON-MONETARY TRANSACTIONS All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.
Compound financial instruments	COMPOUND FINANCIAL INSTRUMENTS The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition. Interest and losses and gains relating to the financial liability are recognized in profit and loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.
Revenue	REVENUE Under International Financial Reporting Standard 15 – Revenue from Contracts with Customers (“IFRS 15”), to determine the amount and timing of revenue to be recognized, the Company follows a five-step model: 1. Identifying the contract with a customer 2. Identifying the performance obligations 3. Determining the transaction price 4. Allocating the transaction price to the performance obligations 5. Recognizing revenue when/as performance obligations are satisfied Cannabis revenue Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods. For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly. Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing. Retail revenue Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives. It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift card. The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price. Franchise revenue Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits. Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and stewarding the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they utilize the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements. Other revenue Proprietary licensing revenue is generated from proprietary licensing services provided to customers. Revenue is recognized when the services are delivered to the customer at a point in time as outlined by the contract. The Company does not operate or manage these services separately from its primary retail sales or operations. Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner. Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.
Research and development	RESEARCH AND DEVELOPMENT Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38. Research and development costs comprise consulting fees, costs to cultivate and test cultivar batches to the point of commercialization and licence acquisition fees. No development costs have been capitalized as at December 31, 2022, or December 31, 2021.
Share-based compensation	SHARE-BASED COMPENSATION The Company’s share-based compensation plans include equity-settled awards and cash-settled awards. The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted. Equity-settled Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted from time to time to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital. Cash-settled DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment. Nova DSUs are granted to Nova directors and represent a right for the holder to receive a cash payment equal to the fair value of Nova’s common shares calculated at the date of such payment, or Nova common shares, at the discretion of Nova. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.
Income taxes	INCOME TAXES Income taxes are recognized in profit and loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity. Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and include any adjustment to income tax payable or recoverable in respect of previous periods. Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable. Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized. Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.
Business combinations	BUSINESS COMBINATIONS Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transaction costs associated with business combinations are expensed as incurred.
Fair value of assets acquired and liabilities assumed in a business combination	FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.
Goodwill	GOODWILL Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in profit and loss. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.
Non-controlling Interests	NON-CONTROLLING INTERESTS The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.
Loss of control	Loss of control When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.
Leases	LEASES A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. As a lessee The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost and any direct costs of obtaining the lease, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease liability. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease liability is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. Lease payments are allocated between the liability and accretion expense. Accretion expense is recognized on the lease liability using the effective interest rate method and payments are applied against the lease liability. The carrying amounts of the right of use assets, lease liability, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset. As a lessor When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right of use asset arising from the head lease, not with reference to the underlying asset.
Government grants	GOVERNMENT GRANTS Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.
Captive insurance	Captive Insurance The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures. The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies International Financial Reporting Standard 10 – Consolidated Financial Statements (“IFRS 10”) in its assessment of control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss). The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.
New accounting standards	NEW ACCOUNTING STANDARDS The following accounting standards were effective for annual periods beginning on or after January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements: • Onerous Contracts — Cost of Fulfilling a Contract — Amendments to IAS 37 • Property, Plant and Equipment: Proceeds before Intended Use — Amendments to IAS 16 There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2023, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2022. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include: • Classification of Liabilities as Current or Non-current — Amendment to IAS 1 • IFRS 17 Insurance Contracts • Definition of Accounting Estimate — Amendments to IAS 8 • Deferred Tax related to Assets and Liabilities arising from a Single Transaction — Amendments to IAS 12

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Significant Accounting Policies [Abstract]
Estimated Use Full Life Of Asset Explanatory	For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below: • Production facilities — 20 years • Equipment — 1 to 10 years • Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Alcanna
Disclosure of detailed information about business combination [line items]
Summary of Purchase Price Allocated	The fair value of consideration paid was as follows: Provisional Adjustments Final Cash 54,339 — 54,339 Issuance of common shares 287,129 — 287,129 341,468 — 341,468
Summary of Fair Value of Assets and Liabilities Acquired	The fair value of the assets and liabilities acquired was as follows: Provisional Adjustments Final Cash 23,190 — 23,190 Accounts receivable 1,868 — 1,868 Prepaid expenses and deposits 10,986 — 10,986 Inventory 105,022 — 105,022 Right of use assets 171,866 ( 31,117 ) 140,749 Property, plant and equipment 86,059 24,632 110,691 Intangible assets — 45,100 45,100 Goodwill 280,243 ( 129,308 ) 150,935 Accounts payable and accrued liabilities ( 36,703 ) ( 44 ) ( 36,747 ) Long-term debt ( 10,000 ) — ( 10,000 ) Lease liabilities ( 232,755 ) 90,736 ( 142,019 ) Derivative warrants ( 58 ) ( 27 ) ( 85 ) Non-controlling interest ( 58,250 ) 28 ( 58,222 ) 341,468 — 341,468
Inner Spirit
Disclosure of detailed information about business combination [line items]
Summary of Purchase Price Allocated	The fair value of consideration paid was as follows: Provisional Adjustments Final Cash 92,583 — 92,583 Issuance of common shares 26,216 — 26,216 Contingent consideration 1,150 — 1,150 119,949 — 119,949
Summary of Fair Value of Assets and Liabilities Acquired	The fair value of the assets and liabilities acquired was as follows: Provisional Adjustments Final Cash 9,808 — 9,808 Accounts receivable 750 ( 327 ) 423 Prepaid expenses and deposits 853 — 853 Inventory 2,733 2,011 4,744 Right of use assets — 5,730 5,730 Property, plant and equipment 12,108 ( 5,730 ) 6,378 Intangible assets — 46,000 46,000 Net investment in subleases 23,751 50 23,801 Goodwill 114,537 ( 42,041 ) 72,496 Accounts payable and accrued liabilities ( 2,678 ) — ( 2,678 ) Convertible debentures ( 12,025 ) — ( 12,025 ) Lease liabilities ( 29,481 ) ( 50 ) ( 29,531 ) Financial guarantee liability ( 407 ) — ( 407 ) Deferred tax liability — ( 5,643 ) ( 5,643 ) 119,949 — 119,949
Zenabis
Disclosure of detailed information about business combination [line items]
Summary of Purchase Price Allocated	The fair value of consideration paid was as follows: Final Extinguishment of senior loan 18,215 18,215
Summary of Fair Value of Assets and Liabilities Acquired	The fair value of the assets and liabilities acquired was as follows: Final Cash 2,509 Accounts receivable 888 Biological assets 909 Prepaid expenses and deposits 1,856 Inventory 4,512 Assets held for sale 6,375 Right of use assets 32 Property, plant and equipment 4,658 Accounts payable and accrued liabilities ( 3,437 ) Lease liabilities ( 87 ) 18,215

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of operating segments [abstract]
Disclosure of Reportable Segments Explanatory	Liquor Retail (1) Cannabis Retail (1) Cannabis (2) Investments (3) Corporate Total As at December 31, 2022 Total assets 351,338 200,393 163,130 825,151 19,338 1,559,350 Year ended December 31, 2022 Net revenue 462,180 205,610 44,407 — — 712,197 Gross margin 106,307 47,334 ( 13,266 ) — — 140,375 Interest and fee revenue — — — 16,739 — 16,739 Investment (loss) income — — — ( 65,164 ) — ( 65,164 ) Share of loss of equity-accounted investees — — — ( 43,002 ) — ( 43,002 ) Depreciation and amortization 17,025 9,920 199 — 13,801 40,945 Income (loss) before income tax 17,726 ( 183,055 ) ( 29,618 ) ( 127,362 ) ( 57,461 ) ( 379,770 ) (1) Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a) ). (2) Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c) ). (3) Total assets include cash and cash equivalents. Liquor Retail Cannabis Retail (1) Cannabis Investments (2) Corporate Total As at December 31, 2021 Total assets (3) — 157,022 147,887 1,093,596 29,155 1,427,660 Year ended December 31, 2021 Net revenue — 16,091 40,037 — — 56,128 Gross margin (3) — 6,498 ( 15,499 ) — — ( 9,001 ) Interest and fee revenue — — — 13,149 — 13,149 Investment loss — — — ( 44,501 ) — ( 44,501 ) Share of profit of equity-accounted investees — — — 32,913 — 32,913 Depreciation and amortization (3) — 1,282 3,108 — 897 5,287 Income (loss) before income tax (3) — ( 410 ) ( 117,990 ) ( 5,837 ) ( 110,461 ) ( 234,698 ) (1) Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021. (2) Total assets include cash and cash equivalents. (3) Adjustments to provisional amounts — refer to note 5(b)

Restricted Cash (Tables)

Restricted Cash (Tables)	12 Months Ended
	Dec. 31, 2022
Restricted Cash [Abstract]
Disclosure of Restricted Cash	As at December 31, 2022 December 31, 2021 Securities collateral — 7,773 Captive insurance 19,044 19,240 Other 294 — 19,338 27,013

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2022
Marketable Securities Disclosure [Abstract]
Disclosure of Marketable Securities	As at December 31, 2022 December 31, 2021 Balance, beginning of year 83,724 — Additions 3,755 158,101 Dispositions — ( 9,663 ) Change in fair value recognized in profit or loss ( 65,553 ) ( 64,714 ) Balance, end of year 21,926 83,724
Schedule of Components of Marketable Securities	The components of marketable securities are as follows: As at December 31, 2022 December 31, 2021 Equity securities 21,926 83,802 Put and call options — ( 78 ) 21,926 83,724

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Summary of Accounts Receivable	As at December 31, 2022 December 31, 2021 Trade receivables 17,558 10,865 Other receivables 5,078 — 22,636 10,865

Biological Assets (Tables)

Biological Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Changes in biological assets [abstract]
Summary of Change in Carrying Value of Biological Assets	The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows: As at December 31, 2022 December 31, 2021 Balance, beginning of year 4,410 3,531 Increase in biological assets due to capitalized costs 27,749 25,880 Acquisition 909 — Net change in fair value of biological assets ( 1,309 ) 4,708 Transferred to inventory upon harvest ( 28,282 ) ( 29,709 ) Balance, end of year 3,477 4,410
Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets	Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows: Assumption Input Weighted average input Effect of 10 % change ($000s) December 31 December 31 December 31 December 31 Yield per square foot of growing space (1) Grams 48 49 279 435 Average net selling price (2) $/gram 4.66 4.49 687 1,014 After harvest cost to complete and sell $/gram 1.27 1.06 187 249 (1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available. (2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Classes of current inventories [abstract]
Summary of Inventories	As at December 31, 2022 December 31, 2021 Retail liquor 82,589 — Harvested cannabis Raw materials, packaging and components 4,577 4,354 Work-in-progress 19,927 19,751 Finished goods 7,040 2,966 Retail cannabis 13,373 2,397 Millwork 276 35 127,782 29,503

Right Of Use Assets (Tables)

Right Of Use Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of quantitative information about right-of-use assets [abstract]
Schedule of Right Of Use Assets	Cost Balance at December 31, 2020 1,894 Acquisition (note 5(b)) 5,730 Additions 579 Dispositions ( 165 ) Balance at December 31, 2021 8,038 Acquisition (note 5(a), note5(c)) 140,781 Additions 6,103 Tenant inducement allowances ( 46 ) Dispositions and remeasurements 12,191 Balance at December 31, 2022 167,067 Accumulated depreciation and impairment Balance at December 31, 2020 571 Depreciation 897 Dispositions ( 147 ) Balance at December 31, 2021 1,321 Depreciation 25,227 Impairment 6,365 Balance at December 31, 2022 32,913 Net book value Balance at December 31, 2021 6,717 Balance at December 31, 2022 134,154

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Schedule of Property Plant and Equipment	Land Production facilities Leasehold improvements Equipment Construction Total Cost Balance at December 31, 2020 8,640 152,935 2 28,894 8,819 199,290 Acquisition (note 5(b)) — — 4,169 2,209 — 6,378 Additions — 467 126 1,975 1,209 3,777 Transfers from CIP 3,748 — — — ( 3,748 ) — Dispositions — ( 70 ) ( 398 ) ( 301 ) ( 177 ) ( 946 ) Balance at December 31, 2021 12,388 153,332 3,899 32,777 6,103 208,499 Acquisition (note 5(a), note5(c)) 130 2,982 65,605 44,263 2,369 115,349 Additions 57 256 3,465 5,907 982 10,667 Dispositions ( 611 ) ( 3,844 ) ( 647 ) ( 4,025 ) — ( 9,127 ) Balance at December 31, 2022 11,964 152,726 72,322 78,922 9,454 325,388 Accumulated depreciation and impairment Balance at December 31, 2020 — 69,364 — 8,500 5,821 83,685 Depreciation — 2,503 411 5,438 — 8,352 Impairment — 60,000 — — — 60,000 Dispositions — — — ( 10 ) — ( 10 ) Balance at December 31, 2021 — 131,867 411 13,928 5,821 152,027 Depreciation — 1,288 7,212 11,373 — 19,873 Impairment — — 7,794 7,415 — 15,209 Dispositions — ( 1,324 ) ( 610 ) ( 3,196 ) — ( 5,130 ) Balance at December 31, 2022 — 131,831 14,807 29,520 5,821 181,979 Net book value Balance at December 31, 2021 12,388 21,465 3,488 18,849 282 56,472 Balance at December 31, 2022 11,964 20,895 57,515 49,402 3,633 143,409

Net Investment In Subleases (Ta

Net Investment In Subleases (Table)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Net Investment In Subleases [Abstract]
Disclosure of Detailed Information Net Investment in Subleases Explanatory	December 31, 2022 December 31, 2021 Balance, beginning of year 26,562 — Acquisition (note 5(b)) — 23,801 Additions 1,408 3,951 Finance income 833 573 Rents recovered (payments made directly to landlords) ( 4,141 ) ( 1,713 ) Dispositions and remeasurements ( 1,343 ) ( 50 ) Balance, end of year 23,319 26,562 Current portion 3,701 3,991 Long-term 19,618 22,571

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about intangible assets [abstract]
Summary of Reconciliation of Changes in Intangible Assets and Goodwill	Brands and trademarks Franchise agreements Software Retail Licenses Total Cost Balance at December 31, 2020 5,445 — — — 5,445 Acquisition (note 5(b)) (1) 36,000 10,000 — — 46,000 Balance at December 31, 2021 41,445 10,000 — — 51,445 Acquisition (note 5(a)) 38,950 — 5,400 750 45,100 Additions 55 — 142 — 197 Dispositions ( 50 ) — — — ( 50 ) Balance at December 31, 2022 80,400 10,000 5,542 750 96,692 Accumulated amortization and impairment Balance at December 31, 2020 382 — — — 382 Amortization (1) 354 561 — — 915 Balance at December 31, 2021 736 561 — — 1,297 Amortization 293 1,250 679 — 2,222 Impairment 18,288 — — — 18,288 Balance at December 31, 2022 19,317 1,811 679 — 21,807 Net book value Balance at December 31, 2021 40,709 9,439 — — 50,148 Balance at December 31, 2022 61,083 8,189 4,863 750 74,885 (1) Adjustment to provisional amounts — refer to note 5(b) .

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Investments [Abstract]
Investments Other Than Investments Accounted for Using Equity Method	As at December 31, 2022 December 31, 2021 Investments at amortized cost 24,493 24,987 Investments at FVTPL 72,761 48,576 97,254 73,563 Current portion 6,552 3,065 Long-term 90,702 70,498

Equity-Accounted Investees (Tab

Equity-Accounted Investees (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Interests In Other Entities [Abstract]
Schedule of Equity Method Investments Table	As at December 31, 2022 December 31, 2021 Interest in joint venture (A) 519,255 412,858 Interest in associate (B) — — 519,255 412,858
Disclosure of joint ventures	The following table summarizes the carrying amount of the Company’s interest in the joint venture: Carrying amount Balance at December 31, 2020 — Capital contributions 395,569 Share of net earnings 32,913 Share of other comprehensive income 9,878 Distributions ( 25,502 ) Balance at December 31, 2021 412,858 Capital contributions 119,137 Share of net earnings (loss) ( 43,002 ) Share of other comprehensive income 31,923 Distributions ( 1,661 ) Balance at December 31, 2022 519,255
Summary of Financial Information of SunStream	The following table summarizes the financial information of SunStream: As at December 31, 2022 December 31, 2021 Current assets (including cash and cash equivalents - 2022: $ 1.5 million, 2021: $ 0.2 million) 5,437 789 Non-current assets 509,418 407,860 Current liabilities ( 1,146 ) ( 1,596 ) Net assets (liabilities) ( 100 %) 513,709 407,053 Year ended December 31 2022 2021 Revenue (loss) ( 35,046 ) 36,203 Profit (loss) from operations ( 42,627 ) 32,841 Other comprehensive income 31,923 9,878 Total comprehensive income (loss) ( 10,619 ) 42,747

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Summary of Accounts Payable and Accrued Liabilities	December 31, 2022 December 31, 2021 Trade payables 9,774 4,172 Accrued and other liabilities 38,379 34,280 48,153 38,452

Derivative Warrants (Tables)

Derivative Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Warrant Liabilities [Abstract]
Summary of Derivative Warrants	December 31, 2022 December 31, 2021 Balance, beginning of year 21,700 428 2021 Series A and B Warrants - fair value on issuance — 62,680 2021 Additional Series A and B Warrants - fair value on issuance — 38,576 New Warrants - fair value on issuance recognized in profit or loss — 106,531 Change in fair value recognized in profit or loss ( 10,783 ) ( 28,697 ) Converted to common shares — ( 157,818 ) Acquisition (note 5(a)) 85 — Balance, end of year 11,002 21,700 The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.
Summary of Outstanding Derivative Warrants	The following table summarizes outstanding derivative warrants as at December 31, 2022: Exercise price (USD) Number of warrants Weighted average contractual life 2020 Series A Warrants (1) 1.77 50,000 2.6 Unsecured Convertible Notes Warrants (1) 1.77 50,000 1.0 New Warrants (2) 2.29 9,833,333 1.6 December 2018 Performance Warrants CAD 5.51 118,067 1.0 10,051,400 1.6 (1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable. (2) The exercise price of the New Warrants was adjusted from USD $ 15.00 to $ 2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a) ).

Lease Liabilities (Tables)

Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Lease liabilities [abstract]
Summary of Lease Liabilities	December 31, 2022 December 31, 2021 Balance, beginning of year 33,470 1,440 Acquisition (note 5(a), note5(c)) 142,106 29,531 Additions 7,497 4,514 Lease payments ( 31,834 ) ( 2,721 ) Dispositions and remeasurements 10,890 ( 70 ) Tenant inducement allowances received 1,799 — Accretion expense 5,903 776 Balance, end of year 169,831 33,470 Current portion 30,206 5,701 Long-term 139,625 27,769
Summary of Minimum Lease Payments	The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company’s lease liabilities as at December 31, 2022: December 31, 2022 Less than one year 39,255 One to three years 64,892 Three to five years 48,955 Thereafter 47,468 Minimum lease payments 200,570

Other Liabilities (Tables)

Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Other Liabilities [Abstract]
Schedule Of Other Liabilities	December 31, 2022 December 31, 2021 Financial guarantee liability (A) 407 466 Deferred share units liability (B) 2,302 4,039 2,709 4,505 a) Financial guarantee liability For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of ECLs in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs (note 28) in the consolidated statement of loss and comprehensive loss. b) DSU liability Deferred share units (“DSUs”) are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder, equal to the fair value of the Company’s common shares calculated at the date of such payment, when a director leaves the board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. Changes in the fair value are recognized within share-based compensation expense (note 24(d) ).

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Major components of tax expense (income) [abstract]
Summary of Income Tax Expense (Recovery)	The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in profit and loss for the years ended December 31, 2022, December 31, 2021 and December 31, 2020: December 31, 2022 December 31, 2021 December 31, 2020 Loss before taxes ( 379,770 ) ( 234,698 ) ( 206,317 ) Statutory income tax rates 23.0 % 23.0 % 24.0 % Expected income tax recovery ( 87,347 ) ( 53,981 ) ( 49,516 ) Non-deductible share-based compensation 2,508 2,308 1,970 Non-deductible finance expense — 2 2,130 Revaluation of the fair value of warrant liabilities ( 2,461 ) 17,902 — Non-controlling interest 8,167 — — Non-deductible portion of capital losses 7,458 5,118 — Other non-deductible expenses 5,409 610 348 Goodwill impairment 35,919 — — Change in tax rates — — 1,528 Deferred tax benefits not recognized 23,005 20,127 43,540 Income tax (recovery) expense ( 7,342 ) ( 7,914 ) —
Summary of Deferred Tax Assets (Liabilities)	Details of the deferred tax assets (liabilities) are as follows: December 31, 2022 December 31, 2021 Deferred tax assets (liabilities): Inventory 23,329 20,472 Biological assets ( 9,451 ) ( 9,509 ) Net investment in subleases ( 5,363 ) ( 6,119 ) Intangible assets ( 16,632 ) — Lease liabilities ( 5,488 ) ( 8,361 ) Marketable securities 14,981 7,442 Equity-accounted investee ( 1,376 ) ( 3,925 ) Net deferred tax asset (liability) — —
Summary of Unrecognized Deductible Temporary Differences	Deferred tax assets have not been recognized for the following deductible temporary differences: December 31, 2022 December 31, 2021 Unrecognized deductible temporary differences: Property, plant and equipment 7,413 81,583 Intangible assets 183 ( 45,256 ) Share issue costs 28,926 23,835 Investments 18,239 3,300 Lease liabilities 193,691 69,865 Financial obligations and other 2,300 4,100 Non-capital losses & scientific research and experimental development 490,326 220,596 Unrecognized deductible temporary differences 741,078 358,023
Summary of Movement in Deferred Income Tax Liability	The movement in deferred income tax liability is as follows: December 31, 2022 December 31, 2021 Balance, beginning of year — — Recognized in profit and loss ( 7,342 ) ( 7,914 ) Recognized in other comprehensive income 7,342 7,914 Balance, end of year — —

Share Capital and Warrants (Tab

Share Capital and Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Share Capital And Warrants [Abstract]
Summary of Issued and Outstanding	b) Issued and outstanding December 31, 2022 December 31, 2021 Note Number of Carrying Number of Carrying Balance, beginning of year 206,040,836 2,035,704 91,884,413 762,046 Share issuances 370,179 2,870 95,680,666 977,425 Share issuance costs — — — ( 16,371 ) Share repurchases ( 4,252,489 ) ( 41,617 ) — — Acquisition 5 32,060,135 287,129 2,443,128 26,216 Convertible debenture settlement — — 248,875 2,671 Derivative warrants exercised — — 15,214,695 277,136 Warrants exercised — — 19,571 178 Employee awards exercised (1) 975,575 8,724 549,488 6,403 Balance, end of year 235,194,236 2,292,810 206,040,836 2,035,704 (1) Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.
Summary of Common Share Purchase Warrants	(C) Common share purchase warrants Number of Warrants Carrying Amount Balance at December 31, 2020 102,400 6,138 Acquisition (note 5(b)) 209,783 1,771 Warrants issued 64,000 361 Warrants exercised ( 19,571 ) ( 178 ) Balance at December 31, 2021 356,612 8,092 Warrants expired ( 48,000 ) ( 5,832 ) Balance at December 31, 2022 308,612 2,260
Summary of Outstanding Warrants	The following table summarizes outstanding warrants as at December 31, 2022: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average Financial services 45.98 54,400 6.6 Acquired from Inner Spirit (1) 3.37 190,212 1.2 Sun 8 9.40 64,000 3.0 $ 12.13 308,612 2.5 (1) Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b) ) and have been presented based on the number of SNDL common shares that are issuable.

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Components of Share-based Compensation Expense	The components of share-based compensation expense are as follows: Year ended 2022 2021 2020 Equity-settled expense Simple warrants (A) 1,299 2,899 1,539 Performance warrants (A) — 361 ( 42 ) Stock options (B) 78 ( 14 ) 651 Restricted share units (1) (C) 9,423 6,789 4,069 Cash-settled expense Deferred share units (1)(2) (D) ( 1,129 ) 2,272 2,349 9,671 12,307 8,566 (1) For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $ 107 and share-based compensation expense under Nova’s DSU plan of $ 404 . (2) Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.
Summary of Changes in Simple and Performance Warrants	The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2022 and the year ended December 31, 2021: Simple Weighted Performance Weighted Balance at December 31, 2020 342,460 $ 44.13 167,200 $ 41.89 Forfeited ( 66,880 ) 33.62 ( 20,480 ) 54.80 Exercised ( 12,000 ) 9.38 ( 8,000 ) 10.94 Expired ( 4,160 ) 34.51 — 0.00 Balance at December 31, 2021 259,420 $ 48.60 138,720 $ 41.77 Forfeited ( 82,400 ) 57.77 ( 15,520 ) 37.86 Expired ( 11,200 ) 6.25 — 0.00 Balance at December 31, 2022 165,820 $ 46.91 123,200 $ 42.26
Summarizes Outstanding Simple and Performance Warrants	The following table summarizes outstanding simple and performance warrants as at December 31, 2022: Warrants outstanding Warrants exercisable Range of exercise prices Number of Weighted Weighted Number of Weighted Weighted Simple warrants $6.25 - $9.38 75,340 7.25 1.40 75,340 7.25 1.40 $29.69 - $45.31 27,120 31.26 1.61 26,320 31.02 1.54 $62.50 - $93.75 49,920 63.50 4.05 49,920 63.50 4.05 $125.00 - $375.00 13,440 239.15 4.62 7,040 205.18 3.70 165,820 $ 46.91 2.49 158,620 $ 37.68 2.36 Performance warrants $6.25 - $9.38 45,066 6.71 n/a 45,066 6.71 2.00 $12.50 - $18.75 17,334 15.15 n/a 17,334 15.15 0.93 $29.69 - $45.31 42,400 31.99 n/a 42,400 31.99 1.22 $62.50 - $93.75 9,334 77.68 n/a 1,334 93.75 1.10 $125.00 - $375.00 9,066 282.36 n/a — — n/a 123,200 $ 42.26 n/a 106,134 $ 19.28 1.91
Summary of Changes in Stock Options	The following table summarizes changes in stock options during the year ended December 31, 2022 and the year ended December 31, 2021: Stock options outstanding Weighted Balance at December 31, 2020 72,060 $ 18.18 Forfeited ( 27,500 ) 26.05 Expired ( 100 ) 31.50 Balance at December 31, 2021 44,460 $ 13.28 Expired ( 100 ) 31.50 Balance at December 31, 2022 44,360 $ 13.24
Summary of Outstanding Stock Options	The following table summarizes outstanding stock options as at December 31, 2022: Stock options outstanding Stock options exercisable Exercise prices Number of Weighted Number of Weighted $11.50 32,500 7.41 21,667 7.41 $11.90 8,160 7.49 8,160 7.49 $31.50 3,700 5.51 3,025 5.38 44,360 7.27 32,852 7.24
Summary of Changes in Restricted Share Units	The following table summarizes changes in RSUs during the year ended December 31, 2022 and the year ended December 31, 2021: RSUs Balance at December 31, 2020 165,692 Granted 1,238,152 Forfeited ( 158,263 ) Exercised ( 491,988 ) Balance at December 31, 2021 753,593 Granted 1,728,557 Forfeited ( 175,245 ) Exercised ( 925,575 ) Balance at December 31, 2022 1,381,330
Summary of Changes in Deferred Share Units	The following table summarizes changes in DSUs during the year ended December 31, 2022 and the year ended December 31, 2021: DSUs Balance at December 31, 2020 332,331 Granted 248,919 Exercised ( 30,000 ) Balance at December 31, 2021 551,250 Granted 1,216,076 Exercised ( 58,943 ) Balance at December 31, 2022 1,708,383 As at December 31, 2022 , nil ( December 31, 2021 – 0.6 million) DSUs were exercisable.

Gross Revenue (Tables)

Gross Revenue (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue [abstract]
Disaggregation of Revenue from Contracts with Customers	Liquor retail revenue is derived from the sale of wines, beers and spirits to customers. Cannabis retail revenue is derived from retail cannabis sales to customers, franchise revenue consists of royalty, advertising and franchise fee revenue, and other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers. Year ended 2022 2021 2020 Liquor retail revenue 462,180 — — Cannabis retail revenue Retail 192,710 10,207 — Franchise 8,337 4,251 — Other 4,563 1,633 — Cannabis retail revenue 205,610 16,091 — Cannabis revenue Provincial boards 58,728 41,338 55,315 Medical 9 8 32 Wholesale 3,167 9,842 17,974 Cannabis revenue 61,904 51,188 73,321 Gross revenue 729,694 67,279 73,321
Summary of Receivables from Contracts with Customers	The Company has recognized the following receivables from contracts with customers: December 31, 2022 December 31, 2021 December 31, 2020 Receivables, included in 'trade receivables' (note 9) 17,558 10,865 15,786

Investment Revenue (Loss) (Tabl

Investment Revenue (Loss) (Tables)	12 Months Ended
	Dec. 31, 2022
Investment Revenue [Abstract]
Summary of Interest and Fee Revenue	Year ended 2022 2021 2020 Interest and fee revenue Interest revenue from investments at amortized cost 3,660 1,654 — Interest and fee revenue from investments at FVTPL 6,036 8,514 — Interest revenue from cash 7,043 2,981 — 16,739 13,149 —
Summary of Investment Loss	Year ended 2022 2021 2020 Investment loss Realized gains 389 20,213 — Unrealized (losses) gains (note 8) ( 65,553 ) ( 64,714 ) — ( 65,164 ) ( 44,501 ) —

Other Operating Expenses (Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Expenses by nature [abstract]
Summary of General and Administrative Expense	a) General and administrative Year ended 2022 2021 (1) 2020 Salaries and wages 80,134 18,675 11,634 Consulting fees 1,934 1,112 2,193 Office and general 37,061 7,560 9,843 Professional fees 11,563 6,530 4,658 Merchant processing fees 4,748 — — Director fees 472 351 365 Other 4,256 3,815 3,336 140,168 38,043 32,029 (1) Adjustment to provisional amounts — refer to note 5(b) .
Summary of Sales and Marketing Expense	b) Sales and marketing Year ended 2022 2021 2020 Marketing 7,308 3,671 4,839 Events 102 191 393 Research — 43 57 Media 1,007 1,138 448 8,417 5,043 5,737

Finance Costs (Tables)

Finance Costs (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Finance Cost [Abstract]
Summary of Finance Costs	Year ended 2022 2021 2020 Cash finance expense Interest on long-term debt — — 7,482 Other finance costs 178 40 286 178 40 7,768 Non-cash finance expense (income) Change in fair value of investments at FVTPL 36,087 3,300 — Accretion on lease liabilities 5,903 776 89 Financial guarantee liability (recovery) expense ( 59 ) 59 — Accretion — — 1,622 Amortization of debt issue costs — — 1,782 Change in fair value of convertible notes — — ( 7,141 ) Other 89 154 ( 86 ) 42,020 4,289 ( 3,734 ) Interest income ( 884 ) ( 573 ) ( 215 ) 41,314 3,756 3,819

Supplemental Cash Flow Disclo_2

Supplemental Cash Flow Disclosures (Tables)	12 Months Ended
	Dec. 31, 2022
Supplemental Cash Flow Disclosure [Abstract]
Summary of Changes in Non-cash Working Capital	Year ended 2022 2021 2020 Cash provided by (used in): Accounts receivable ( 5,815 ) 9,339 ( 2,037 ) Biological assets 533 3,829 13,789 Inventory 4,243 ( 18,318 ) ( 12,315 ) Prepaid expenses and deposits 5,782 ( 3,922 ) 2,280 Investments 918 ( 402 ) — Right of use assets ( 17,510 ) — — Property, plant and equipment 38 ( 305 ) — Accounts payable and accrued liabilities ( 27,864 ) 9,665 ( 20,793 ) Lease liabilities 19,296 — — ( 20,379 ) ( 114 ) ( 19,076 ) Changes in non-cash working capital relating to: Operating ( 22,073 ) 150 ( 5,259 ) Investing 74 ( 612 ) ( 11,319 ) Financing 1,620 348 ( 2,498 ) ( 20,379 ) ( 114 ) ( 19,076 ) Cash interest paid — — 6,094

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
Summary of Loss Per Share	Year ended 2022 2021 2020 Weighted average shares outstanding (000s) Basic and diluted (1) 229,871 186,038 21,865 Continuing operations Net loss attributable to owners of the Company ( 335,114 ) ( 226,984 ) ( 199,619 ) Per share - basic and diluted $ ( 1.46 ) $ ( 1.22 ) $ ( 9.13 ) Discontinued operations Net loss attributable to owners of the Company — — ( 33,627 ) Per share - basic and diluted $ — $ — $ ( 1.54 ) Net loss attributable to owners of the Company ( 335,114 ) ( 226,984 ) ( 233,246 ) Per share - basic and diluted $ ( 1.46 ) $ ( 1.22 ) $ ( 10.67 ) (1) For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs t hat were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of detailed information about financial instruments [abstract]
Fair value measurements of marketable securities, investments at FVTPL and derivative warrants	Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows: Fair value measurements using December 31, 2022 Carrying Level 1 Level 2 Level 3 Recurring measurements: Financial assets Marketable securities 21,926 21,926 — — Investments at FVTPL 72,761 — — 72,761 Financial liabilities Derivative warrants (1) 11,002 — — 11,002 Fair value measurements using December 31, 2021 Carrying Level 1 Level 2 Level 3 Recurring measurements: Financial assets Marketable securities 83,724 83,724 — — Investments at FVTPL 48,576 — — 48,576 Financial liabilities Derivative warrants (1) 21,700 — — 21,700 (1) The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.
Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss	Impairment losses on accounts receivable recognized in profit or loss were as follows: As at December 31, 2022 December 31, 2021 Impairment loss (reversal) on trade receivables 642 214 Impairment loss (reversal) on other receivables 674 798 1,316 1,012
Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable	The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2022 was as follows: December 31, 2022 December 31, 2021 Balance, beginning of year 1,132 120 Net remeasurement of impairment loss allowance 1,316 1,012 Balance, end of year 2,448 1,132
Timing of Expected Cash Outflows Relating to Financial Liabilities	The timing of expected cash outflows relating to financial liabilities at December 31, 2022 is as follows: Less than One to three Three to five Thereafter Total Accounts payable and accrued liabilities 48,153 — — — 48,153 Financial guarantee liability (note 21) — 407 — — 407 Balance, end of year 48,153 407 — — 48,560

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related party transactions [abstract]
Compensation of Key Management Personnel	Compensation of key management personnel The Company considers directors and officers of the Company as key management personnel. Year ended 2022 2021 2020 Salaries and short-term benefits 4,505 2,348 1,944 Share-based compensation 5,871 8,275 7,629 10,376 10,623 9,573

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of Non Controlling Interests [Abstract]
Summary of detailed information about non material non-controlling interests	The Company does have subsidiaries with non-material non-controlling interests that are not presented in the following financial information. a) Nova summarized statement of financial position 2022 Current assets 18,732 Current liabilities 19,892 Current net assets ( 1,160 ) Non-current assets 94,419 Non-current liabilities 45,443 Non-current net assets 48,976 Net assets 47,816 b) Nova summarized statement of loss and comprehensive loss 2022 Revenue 176,588 Loss and comprehensive loss ( 7,672 ) c) Nova summarized statement of cash flows 2022 Net cash provided by operating activities 5,848 Net cash used in investing activities ( 5,549 ) Net cash used in financing activities ( 183 ) Increase in cash 116

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Significant Accounting Policies [Line Items]
Depreciation method, property, plant and equipment	straight-line method
Onerous contracts provision	$ 0	$ 0
Gain loss on conversion of financial liability reclassified to equity	0
Development costs capitalized	$ 0	$ 0
Sun 8 Holdings Inc
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	15 years
World Wide Proprietary Rights
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	12 years
Inner Spirit
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	8 years
Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturities period	90 days

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Production Facilities
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	20 years
Equipment | Bottom of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	1 year
Equipment | Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	10 years
Right of Use Assets and Leasehold Improvements
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	Shorter of estimated useful life or lease term

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details)							2 Months Ended	3 Months Ended				5 Months Ended		7 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
		Sep. 30, 2022 CAD ($)	Mar. 31, 2022 CAD ($) shares $ / shares	Aug. 04, 2021 CAD ($) shares	Jul. 20, 2021 CAD ($) shares	Jun. 20, 2021	Dec. 31, 2022 CAD ($)	Mar. 30, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Sep. 30, 2021 CAD ($)	Dec. 31, 2021 CAD ($)		Jul. 19, 2021 CAD ($)	Dec. 31, 2022 CAD ($)	Oct. 31, 2022 CAD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)	Dec. 31, 2019 CAD ($)
Disclosure Of Business Combinations [Line Items]
Convertible debenture settlement																	$ 0	$ 9,354,000	[1]	$ 0
Equity component							$ 1,327,655,000		$ 1,329,533,000			$ 1,329,533,000			$ 1,327,655,000		1,327,655,000	1,329,533,000		269,695,000	$ 221,198,000
Liabilities component							231,695,000		98,127,000	[2]		98,127,000	[2]		231,695,000		231,695,000	98,127,000	[2]
Assets component							1,559,350,000		1,427,660,000	[2],[3]		1,427,660,000	[2],[3]		1,559,350,000		1,559,350,000	1,427,660,000	[2],[3]
Intangible assets	[2]						74,885,000		50,148,000			50,148,000			74,885,000		74,885,000	50,148,000
Impairment loss																	$ 196,033,000	60,000,000	[4]	79,191,000
Estimated cash flow term																	5 years
Issued Capital
Disclosure Of Business Combinations [Line Items]
Number of shares issued to settle convertible instruments, Shares | shares				2,500,000
Number of shares issued to settle convertible instruments, Value				$ 2,700,000
Convertible debenture settlement				$ 9,300,000
Equity component							2,292,810,000		2,035,704,000			2,035,704,000			2,292,810,000		$ 2,292,810,000	2,035,704,000		$ 762,046,000	$ 509,654,000
Brands and Trademarks
Disclosure Of Business Combinations [Line Items]
Intangible assets							61,083,000		40,709,000			40,709,000			61,083,000		$ 61,083,000	40,709,000
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Business combination, Transaction end date						Jul. 20, 2021
Description of acquiree																	Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that included more than 100 franchised and corporate-owned locations at the acquisition date.
Cash consideration					$ 92,583,000
Cash transferred for each ordinary shares of acquire					$ 0.30
Issuance of common shares | shares					2,400,000
Issuance of common shares, value					$ 26,216,000
Number of instruments or interests issued or issuable for each ordinary shares of acquire | shares					0.00835
Contingent consideration					$ 1,150,000
Equity component									1,800,000			1,800,000						1,800,000
Liabilities component									300,000			300,000						300,000
Assets component									900,000			900,000						900,000
Revenue												16,100,000
Net earnings (loss)												1,100,000
Revenue increased amount														$ 20,400,000
Net income (loss)														$ (7,400,000)
Acquisition-related costs for business transaction																		1,900,000
Intangible assets									45,400,000			45,400,000						$ 45,400,000
Increase in fair value of intangible assets												46,000,000
Amortization of intangible assets												$ 600,000
Deferred tax liability					(5,643,000)
Goodwill					72,496,000
Inner Spirit | Adjustments
Disclosure Of Business Combinations [Line Items]
Deferred tax liability					(5,643,000)
Increase in amortization expense					600,000				$ 300,000		$ 300,000
Cost of sales					2,000,000
Decrease in general and administrative expenses					300,000
Goodwill					(42,041,000)
Inner Spirit | Group CGU
Disclosure Of Business Combinations [Line Items]
Goodwill		$ 72,500,000					$ 4,600,000								4,600,000		$ 4,600,000
Impairment loss		$ 67,900,000
Estimated cash flow term		5 years
Discount rate		19.50%
Goodwill, Estimated Recoverable Amount		$ 40,000,000
Increase impairment discount rate		1%
Increase of impairment on assets		$ 1,100,000
Inner Spirit | Inner Spirit Warrants
Disclosure Of Business Combinations [Line Items]
Contingent consideration					$ 1,200,000
Inner Spirit | Brands and Trademarks
Disclosure Of Business Combinations [Line Items]
Estimated cash flow term		5 years
Discount rate		19.50%
Inner Spirit | Brands and Trademarks | Cannabis Franchise CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life		$ 18,300,000
Inner Spirit | Brands and Trademarks | Cannabis Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life		17,700,000
Impairment of intangible assets with indefinite useful lives		16,400,000
Intangible Assets With Indefinite, Estimated Recoverable Amount		$ 1,900,000
Alcanna
Disclosure Of Business Combinations [Line Items]
Business Combination Transaction Initiated Date																	Jan. 06, 2022
Business combination, Transaction end date			Mar. 31, 2022
Description of acquiree																	Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”.
Cash consideration			$ 54,339,000
Cash transferred for each ordinary shares of acquire			$ 1.50
Issuance of common shares | shares			32,100,000
Issuance of common shares, value			$ 287,129,000
Number of instruments or interests issued or issuable for each ordinary shares of acquire | shares			0.885
Revenue															639,500,000
Net earnings (loss)															$ 101,000,000
Revenue increased amount								$ 162,500,000
Net income (loss)								$ (25,500,000)
Acquisition-related costs for business transaction																	$ 7,000,000
Percentage of fair value of non-controlling			37%
Share price transaction | $ / shares			$ 2.66
Payment of acquired long-term debt			$ 10,000,000
Goodwill			150,935,000
Estimated cash flow term																	5 years
Discount rate							12%								12%		12%
Alcanna | Adjustments
Disclosure Of Business Combinations [Line Items]
Goodwill			$ (129,308,000)
Alcanna | Cannabis Franchise CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							$ 18,300,000								$ 18,300,000		$ 18,300,000
Alcanna | Cannabis Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							2,700,000								2,700,000		2,700,000
Goodwill							126,600,000								126,600,000		126,600,000
Impairment loss																	88,000,000
Estimated recoverable amount							84,800,000								84,800,000		84,800,000
Alcanna | Liquor Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							43,100,000								43,100,000		43,100,000
Goodwill							24,300,000								$ 24,300,000		24,300,000
Zenabis
Disclosure Of Business Combinations [Line Items]
Revenue							400,000
Net earnings (loss)							$ 1,800,000
Revenue increased amount																$ 2,000,000
Net income (loss)																$ 9,000,000
Acquisition-related costs for business transaction																	$ 800,000
Nova | Alcanna
Disclosure Of Business Combinations [Line Items]
Percentage of equity interest			63%
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b) Adjustment to provisional amounts — refer to note 5(b) .

Business Acquisitions - Summary

Business Acquisitions - Summary of Purchase Price Allocated (Details) - CAD ($) $ in Thousands	Nov. 01, 2022	Mar. 31, 2022	Jul. 20, 2021
Alcanna
Disclosure of detailed information about business combination [line items]
Cash		$ 54,339
Issuance of common shares		287,129
Total Purchase Price		341,468
Inner Spirit
Disclosure of detailed information about business combination [line items]
Cash			$ 92,583
Issuance of common shares			26,216
Contingent consideration			1,150
Total Purchase Price			119,949
Zenabis
Disclosure of detailed information about business combination [line items]
Extinguishment of senior loan	$ 18,215
Total Purchase Price	$ 18,215
Previously Reported | Alcanna
Disclosure of detailed information about business combination [line items]
Cash		54,339
Issuance of common shares		287,129
Total Purchase Price		$ 341,468
Previously Reported | Inner Spirit
Disclosure of detailed information about business combination [line items]
Cash			92,583
Issuance of common shares			26,216
Contingent consideration			1,150
Total Purchase Price			$ 119,949

Business Acquisitions - Summa_2

Business Acquisitions - Summary of Fair Value of the Assets and Liabilities Acquired (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Nov. 01, 2022	Mar. 31, 2022	Dec. 31, 2021	Jul. 20, 2021	Dec. 31, 2020
Disclosure Of Business Combinations [Line Items]
Net investment in subleases	$ 23,319			$ 26,562		$ 0
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Cash					$ 9,808
Accounts receivable					423
Prepaid expenses and deposits					853
Inventory					4,744
Right of use assets					5,730
Property, plant and equipment					6,378
Intangible assets					46,000
Net investment in subleases					23,801
Goodwill					72,496
Accounts payable and accrued liabilities					(2,678)
Convertible debentures					(12,025)
Lease liabilities					(29,531)
Financial guarantee liability					(407)
Deferred tax liability					(5,643)
Total Purchase Price					119,949
Inner Spirit | Previously Reported
Disclosure Of Business Combinations [Line Items]
Cash					9,808
Accounts receivable					750
Prepaid expenses and deposits					853
Inventory					2,733
Property, plant and equipment					12,108
Net investment in subleases					23,751
Goodwill					114,537
Accounts payable and accrued liabilities					(2,678)
Convertible debentures					(12,025)
Lease liabilities					(29,481)
Financial guarantee liability					(407)
Total Purchase Price					119,949
Inner Spirit | Adjustments
Disclosure Of Business Combinations [Line Items]
Accounts receivable					(327)
Inventory					2,011
Right of use assets					5,730
Property, plant and equipment					(5,730)
Intangible assets					46,000
Net investment in subleases					50
Goodwill					(42,041)
Lease liabilities					(50)
Deferred tax liability					$ (5,643)
Alcanna
Disclosure Of Business Combinations [Line Items]
Cash			$ 23,190
Accounts receivable			1,868
Prepaid expenses and deposits			10,986
Inventory			105,022
Right of use assets			140,749
Property, plant and equipment			110,691
Intangible assets			45,100
Goodwill			150,935
Accounts payable and accrued liabilities			(36,747)
Long-term debt			(10,000)
Lease liabilities			(142,019)
Derivative warrants			(85)
Non-controlling interest			(58,222)
Total Purchase Price			341,468
Alcanna | Previously Reported
Disclosure Of Business Combinations [Line Items]
Cash			23,190
Accounts receivable			1,868
Prepaid expenses and deposits			10,986
Inventory			105,022
Right of use assets			171,866
Property, plant and equipment			86,059
Goodwill			280,243
Accounts payable and accrued liabilities			(36,703)
Long-term debt			(10,000)
Lease liabilities			(232,755)
Derivative warrants			(58)
Non-controlling interest			(58,250)
Total Purchase Price			341,468
Alcanna | Adjustments
Disclosure Of Business Combinations [Line Items]
Right of use assets			(31,117)
Property, plant and equipment			24,632
Intangible assets			45,100
Goodwill			(129,308)
Accounts payable and accrued liabilities			(44)
Lease liabilities			90,736
Derivative warrants			(27)
Non-controlling interest			$ 28
Zenabis
Disclosure Of Business Combinations [Line Items]
Cash		$ 2,509
Accounts receivable		888
Biological assets		909
Prepaid expenses and deposits		1,856
Inventory		4,512
Assets held for sale		6,375
Right of use assets		32
Property, plant and equipment		4,658
Accounts payable and accrued liabilities		(3,437)
Lease liabilities		(87)
Total Purchase Price		$ 18,215

Discontinued Operations - Summa

Discontinued Operations - Summary Results of Discontinued Operations (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure of analysis of single amount of discontinued operations [line items]
Gross revenue		$ 729,694	$ 67,279	[1]	$ 73,321
Net revenue		712,197	56,128	[1]	60,918
Cost of sales	[1]	558,089	50,612		51,740
Gross margin before fair value adjustments		147,096	(11,462)	[1]	(36,735)
Change in fair value of biological assets		(1,309)	4,708	[1]	5,432
Gross margin		140,375	(9,001)	[1],[2]	(49,869)
General and administrative	[1]	140,168	38,043		32,029
Sales and marketing		8,417	5,043	[1]	5,737
Depreciation and amortization	[1]	40,945	5,287	[2]	4,711
Share-based compensation		9,671	12,307	[1]	8,566
Loss from operations		(347,774)	(134,376)	[1]	(185,404)
Transaction costs		(1,352)	(17,566)	[1]	(3,587)
Finance costs, net		(41,314)	(3,756)	[1]	(3,819)
Gain on disposition of PP&E		(94)	235	[1]	488
Loss on disposition of Bridge Farm					(33,627)
Loss before income tax		(379,770)	(234,698)	[1],[2]	(206,317)
Income tax recovery	[1]	7,342	7,914
Net loss		$ (372,428)	$ (226,784)	[1]	$ (239,944)
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b)

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Effect of Disposal on Financial Position (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2019
Disclosure of analysis of single amount of discontinued operations [line items]
Cash and cash equivalents		$ 60,376	[1]	$ 279,586	$ 558,251	[2]	$ 45,337
Accounts receivable				22,636	10,865	[2]
Biological assets		3,531		3,477	4,410	[2]
Inventory				127,782	29,503	[2]
Property, plant and equipment				143,409	56,472	[2]
Goodwill	[2]			67,260	72,496
Intangible assets	[2]			74,885	50,148
Accounts payable and accrued liabilities				(48,153)	(38,452)	[2]
Lease obligation				(139,625)	(27,769)	[2]
Accumulated other comprehensive income				$ (32,188)	$ (7,607)	[2]
Consideration received
Net loss from discontinued operations		$ (33,627)
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Segment Information - Additiona

Segment Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 CAD ($) Segment		Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)
Disclosure Of Operating Segments [Line Items]
Number of reportable segments | Segment	4
Equity-accounted investees	$ 519,255		$ 412,858	[1]
Share of profit (loss) of equity-accounted investees	$ (43,002)		32,913	[2]	$ 0
Liquor Retail | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Liquor retail includes the sale of wines, beers and spirits through owned liquor stores.
Cannabis Retail | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores.
Cannabis Operations | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export.
Investments | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Investments include the deployment of capital to investment opportunities.
Share of profit (loss) of equity-accounted investees	$ (43,002)	[3]	$ 32,913	[4]
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) . Total assets include cash and cash equivalents. Total assets include cash and cash equivalents.

Segment Information - Disclosur

Segment Information - Disclosure of Reportable Segments Explanatory (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Operating Segments [Line Items]
Total assets		$ 1,559,350		$ 1,427,660	[1],[2]
Net revenue		712,197		56,128	[3]	$ 60,918
Gross margin		140,375		(9,001)	[2],[3]	(49,869)
Interest and fee revenue		16,739		13,149
Investment (loss) income		(65,164)		(44,501)
Share of profit (loss) of equity-accounted investees		(43,002)		32,913	[3]	0
Depreciation and amortization	[3]	40,945		5,287	[2]	4,711
Income (loss) before income tax		(379,770)		(234,698)	[2],[3]	$ (206,317)
Operating segments [member] | Liquor Retail
Disclosure Of Operating Segments [Line Items]
Total assets	[4]	351,338
Net revenue	[4]	462,180
Gross margin	[4]	106,307
Depreciation and amortization	[4]	17,025
Income (loss) before income tax	[4]	17,726
Operating segments [member] | Cannabis Retail
Disclosure Of Operating Segments [Line Items]
Total assets		200,393	[4]	157,022	[2],[5]
Net revenue		205,610	[4]	16,091	[5]
Gross margin		47,334	[4]	6,498	[2],[5]
Depreciation and amortization		9,920	[4]	1,282	[2],[5]
Income (loss) before income tax		(183,055)	[4]	(410)	[2],[5]
Operating segments [member] | Cannabis Operations
Disclosure Of Operating Segments [Line Items]
Total assets		163,130	[6]	147,887	[2]
Net revenue		44,407	[6]	40,037
Gross margin		(13,266)	[6]	(15,499)	[2]
Depreciation and amortization		199	[6]	3,108	[2]
Income (loss) before income tax		(29,618)	[6]	(117,990)	[2]
Operating segments [member] | Investments
Disclosure Of Operating Segments [Line Items]
Total assets		825,151	[7]	1,093,596	[2],[8]
Interest and fee revenue		16,739	[7]	13,149	[8]
Investment (loss) income		(65,164)	[7]	(44,501)	[8]
Share of profit (loss) of equity-accounted investees		(43,002)	[7]	32,913	[8]
Income (loss) before income tax		(127,362)	[7]	(5,837)	[2],[8]
Corporate
Disclosure Of Operating Segments [Line Items]
Total assets		19,338		29,155	[2]
Depreciation and amortization		13,801		897	[2]
Income (loss) before income tax		$ (57,461)		$ (110,461)	[2]
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b) Adjustment to provisional amounts — refer to note 5(b) . Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a) ). Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021. Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c) ). Total assets include cash and cash equivalents. Total assets include cash and cash equivalents.

Restricted Cash - Summary of Di

Restricted Cash - Summary of Disclosure of Restricted Cash (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Restricted Cash [Abstract]
Securities collateral	$ 0	$ 7,773
Captive insurance	19,044	19,240
Other	294	0
Restricted cash and cash equivalents	$ 19,338	$ 27,013	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Marketable Securities - Disclos

Marketable Securities - Disclosure of Marketable Securities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Marketable Securities Disclosure [Abstract]
Balance, beginning of year	$ 83,724	[1]	$ 0
Additions	3,755		158,101
Dispositions	0		(9,663)
Change in fair value recognized in profit or loss	(65,553)		(64,714)
Balance, end of year	$ 21,926		$ 83,724	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable Securities Disclosure [Abstract]
Proceeds from disposition of marketable securities	$ 0	$ 29,900,000
Gain on disposition of marketable securities	$ 0	$ 20,200,000

Marketable Securities - Schedul

Marketable Securities - Schedule of Components of Marketable Securities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Components Of Marketable Securities [Abstract]
Equity securities	$ 21,926	$ 83,802
Put and call options	0	(78)
Financial Assets Marketable Securities Current	$ 21,926	$ 83,724	[1]	$ 0
[1] Adjustment to provisional amounts — refer to note 5(b) .

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables	$ 17,558	$ 10,865
Other receivables	5,078
Accounts receivable	$ 22,636	$ 10,865	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Biological Assets - Summary of

Biological Assets - Summary of Change in Carrying Value of Biological Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Changes in biological assets [abstract]
Balance, beginning of year	$ 4,410	[1]	$ 3,531
Increase in biological assets due to capitalized costs	27,749		25,880
Acquisition	909
Net change in fair value of biological assets	(1,309)		4,708
Transferred to inventory upon harvest	(28,282)		(29,709)
Balance, end of year	$ 3,477		$ 4,410	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Biological Assets - Summary o_2

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Details) $ in Thousands		12 Months Ended
		Dec. 31, 2022 CAD ($) Quantity	Dec. 31, 2021 CAD ($) Quantity
Yield per Square Foot of Growing Space
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	[1]	$ 279	$ 435
Average Net Selling Price
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	[2]	687	1,014
After Harvest Cost to Complete and Sell
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $		$ 187	$ 249
Weighted Average Input
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Yield per square foot of growing space | Quantity	[1]	48	49
Average net selling price | Quantity	[2]	4.66	4.49
After harvest cost to complete and sell | Quantity		1.27	1.06
[1] Varies by strain; obtained through historical growing results or grower estimate if historical results are not available. Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

Biological Assets - Summary o_3

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2022
Changes in biological assets [abstract]
Percentage of assumption of effect change	10%

Biological Assets - Additional

Biological Assets - Additional Information (Details) - kg	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Changes in biological assets [abstract]
Estimated biological assets to be harvested	3,904	5,672
Harvested biological assets	19,854	22,784

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Inventories [Line Items]
Inventory	$ 127,782	$ 29,503	[1]
Retail Liquor
Disclosure Of Inventories [Line Items]
Inventory	82,589	0
Harvested Cannabis
Disclosure Of Inventories [Line Items]
Raw materials, packaging and components	4,577	4,354
Work-in-progress	19,927	19,751
Finished goods	7,040	2,966
Retail Cannabis
Disclosure Of Inventories [Line Items]
Inventory	13,373	2,397
Millwork
Disclosure Of Inventories [Line Items]
Inventory	$ 276	$ 35
[1] Adjustment to provisional amounts — refer to note 5(b) .

Inventory - Additional Informat

Inventory - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Classes of current inventories [abstract]
Inventories recognized as expense	$ 558.1	$ 50.6
Inventory write downs	8.9	17.5
Excess and obsolete inventory provision	7	17
Fair value component of excess and obsolete inventory provision	$ 1.9	$ 0.5

Right Of Use Assets - Schedule

Right Of Use Assets - Schedule of Right Of Use Assets (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disclosure of quantitative information about right-of-use assets [line items]
Net book value	[1]	$ 56,472
Impairment		12,800
Dispositions			$ 0
Net book value		143,409	56,472	[1]
Cost
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		208,499	199,290
Acquisition (note 5)		115,349	6,378
Additions		10,667	3,777
Dispositions		(9,127)	(946)
Net book value		325,388	208,499
Accumulated Depreciation and Impairment
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		152,027	83,685
Depreciation		19,873	8,352
Impairment		15,209	60,000
Dispositions		(5,130)	(10)
Net book value		181,979	152,027
Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		6,717
Impairment		6,400
Net book value		134,154	6,717
Right of Use Assets | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		8,038	1,894
Acquisition (note 5)		140,781	5,730
Additions		6,103	579
Dispositions			(165)
Tenant inducement allowances		(46)
Dispositions and remeasurements		12,191
Net book value		167,067	8,038
Right of Use Assets | Accumulated Depreciation and Impairment
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		1,321	571
Depreciation		25,227	897
Impairment		6,365
Dispositions			(147)
Net book value		$ 32,913	$ 1,321
[1] Adjustment to provisional amounts — refer to note 5(b) .

Right Of Use Assets - Additiona

Right Of Use Assets - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	$ 12.8
Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	6.4
Cannabis Retail Reporting Segment
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	5.3
Cannabis Retail Reporting Segment | Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	3.9
Liquor Retail Reporting Segment
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	7.5
Liquor Retail Reporting Segment | Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	$ 2.5

Property Plant and Equipment -

Property Plant and Equipment - Schedule of Property Plant and Equipment (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	[1]	$ 56,472
Impairment		12,800
Dispositions			$ 0
Net book value		143,409	56,472	[1]
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		208,499	199,290
Acquisition (note 5)		115,349	6,378
Additions		10,667	3,777
Transfers from CIP			0
Dispositions		(9,127)	(946)
Net book value		325,388	208,499
Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		152,027	83,685
Depreciation		19,873	8,352
Impairment		15,209	60,000
Dispositions		(5,130)	(10)
Net book value		181,979	152,027
Land
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		12,388
Additions			0
Net book value		11,964	12,388
Land | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		12,388	8,640
Acquisition (note 5)		130	0
Additions		57
Transfers from CIP			3,748
Dispositions		(611)	0
Net book value		11,964	12,388
Land | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		0	0
Depreciation		0	0
Impairment		0	0
Dispositions		0	0
Net book value		0	0
Production Facilities
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		21,465
Net book value		20,895	21,465
Production Facilities | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		153,332	152,935
Acquisition (note 5)		2,982	0
Additions		256	467
Transfers from CIP			0
Dispositions		(3,844)	(70)
Net book value		152,726	153,332
Production Facilities | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		131,867	69,364
Depreciation		1,288	2,503
Impairment		0	60,000
Dispositions		(1,324)	0
Net book value		131,831	131,867
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		3,488
Net book value		57,515	3,488
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		3,899	2
Acquisition (note 5)		65,605	4,169
Additions		3,465	126
Transfers from CIP			0
Dispositions		(647)	(398)
Net book value		72,322	3,899
Leasehold Improvements | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		411	0
Depreciation		7,212	411
Impairment		7,794	0
Dispositions		(610)	0
Net book value		14,807	411
Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		18,849
Net book value		49,402	18,849
Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		32,777	28,894
Acquisition (note 5)		44,263	2,209
Additions		5,907	1,975
Transfers from CIP			0
Dispositions		(4,025)	(301)
Net book value		78,922	32,777
Equipment | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		13,928	8,500
Depreciation		11,373	5,438
Impairment		7,415	0
Dispositions		(3,196)	(10)
Net book value		29,520	13,928
Construction in Progress
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		282
Net book value		3,633	282
Construction in Progress | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		6,103	8,819
Acquisition (note 5)		2,369	0
Additions		982	1,209
Transfers from CIP			(3,748)
Dispositions		0	(177)
Net book value		9,454	6,103
Construction in Progress | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		5,821	5,821
Depreciation		0	0
Impairment			0
Dispositions			0
Net book value		$ 5,821	$ 5,821
[1] Adjustment to provisional amounts — refer to note 5(b) .

Property Plant and Equipment _2

Property Plant and Equipment - Additional Information (Details)	3 Months Ended	12 Months Ended
	Jun. 30, 2021 CAD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, capitalized to biological assets and inventory		$ 6,400,000	$ 4,900,000
Estimated cash flow term		5 years
Asset impairment		$ 196,033,000	$ 60,000,000	[1]	$ 79,191,000
Impairment		$ 12,800,000
EBITDA forecast extension period		5 years
Cash flows increased by a terminal growth rate		2.50%
Cannabis Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 5,300,000
Liquor Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 7,500,000
Weighted Average Cost of Capital
Disclosure of detailed information about property, plant and equipment [line items]
Significant unobservable input		12
Idle Machinery and Equipment | Cannabis Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 2,400,000
Merritt Facility
Disclosure of detailed information about property, plant and equipment [line items]
Proceeds from disposition		3,500,000
Fair value less costs of disposal and impairment		500,000
Rocky View Facility
Disclosure of detailed information about property, plant and equipment [line items]
Proceeds from disposition		3,900,000
Fair value less costs of disposal and impairment		$ 0
Old Cash Generating Units
Disclosure of detailed information about property, plant and equipment [line items]
Impairment discount rate	25%
Estimated cash flow term	5 years
Asset impairment	$ 60,000,000
Increase impairment discount rate		1%
Increase of impairment on assets		$ 7,300,000
Alberta CGU
Disclosure of detailed information about property, plant and equipment [line items]
Estimated recoverable amount	$ 70,000,000
[1] Adjustment to provisional amounts — refer to note 5(b) .

Net Investment In Subleases - S

Net Investment In Subleases - Summary of Net Investment in Subleases (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Net Investment In Subleases [Abstract]
Balance, beginning of year	$ 26,562	$ 0
Acquisition (note 5(b))	0	23,801
Additions	1,408	3,951
Finance income	833	573
Rents recovered (payments made directly to landlords)	(4,141)	(1,713)
Dispositions and remeasurement	(1,343)	(50)
Balance, end of year	23,319	26,562
Current portion	3,701	3,991	[1]
Long-term	$ 19,618	$ 22,571	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Intangible Assets - Summary of

Intangible Assets - Summary of Reconciliation of Changes in Intangible Assets and Goodwill (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	[1]	$ 50,148
Depreciation	[2]	40,945	$ 5,287	[3]	$ 4,711
Ending Balance	[1]	74,885	50,148
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		51,445	5,445
Acquisition		45,100	46,000	[4]
Additions		197
Dispositions		(50)
Ending Balance		96,692	51,445		5,445
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		1,297	382
Amortization		2,222	915	[4]
Impairment		18,288
Ending Balance		21,807	1,297		382
Brands and Trademarks
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		40,709
Ending Balance		61,083	40,709
Brands and Trademarks | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		41,445	5,445
Acquisition		38,950	36,000	[4]
Additions		55
Dispositions		(50)
Ending Balance		80,400	41,445		5,445
Brands and Trademarks | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		736	382
Amortization		293	354	[4]
Impairment		18,288
Ending Balance		19,317	736		382
Franchises Agreements
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		9,439
Ending Balance		8,189	9,439
Franchises Agreements | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		10,000	0
Acquisition		0	10,000	[4]
Additions		0
Dispositions		0
Ending Balance		10,000	10,000		0
Franchises Agreements | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		561	0
Amortization		1,250	561	[4]
Impairment		0
Ending Balance		1,811	561		0
Software
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0
Ending Balance		4,863	0
Software | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Acquisition		5,400	0	[4]
Additions		142
Dispositions		0
Ending Balance		5,542	0		0
Software | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Amortization		679	0	[4]
Impairment		0
Ending Balance		679	0		0
Retail Licenses
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0
Ending Balance		750	0
Retail Licenses | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Acquisition		750	0	[4]
Additions		0
Dispositions		0
Ending Balance		750	0		0
Retail Licenses | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Amortization		0	0	[4]
Impairment		0
Ending Balance		$ 0	$ 0		$ 0
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b) Adjustment to provisional amounts — refer to note 5(b) .

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - CAD ($) $ in Millions		3 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022
Cannabis Retail
Disclosure Of Intangible Assets [Line Items]
Impairment of intangible assets with indefinite useful lives	$ 16.4
Inner Spirit
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			8 years
Other Intellectual Property
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			12 years
Sun 8 Holdings Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			15 years
Impairment		$ 1.9
Estimated recoverable amount	$ 2.5	$ 2.5

Investments - Investments Other

Investments - Investments Other Than Investments Accounted for Using Equity Method (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 97,254	$ 73,563
Investments	6,552	3,065	[1]
Long-term	90,702	70,498	[1]
Financial assets at amortized cost, category | At cost
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	24,493	24,987
Financial assets at fair value through profit or loss, category | At fair value
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 72,761	$ 48,576
[1] Adjustment to provisional amounts — refer to note 5(b) .

Investments - Additional Inform

Investments - Additional Information (Details) - CAD ($) $ in Millions								12 Months Ended
	Jan. 02, 2023	Dec. 31, 2022	Nov. 01, 2022	Aug. 26, 2022	Aug. 22, 2022	Mar. 30, 2022	Feb. 09, 2022	Dec. 31, 2022
ZENABIS
Disclosure Of Transactions Between Related Parties [Line Items]
Adjusted fair value of senior loan			$ 33.7
SUPERETTE | Promissory Notes
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument							$ 5
Maturity date of investments							Feb. 09, 2025
Rate of interest on investments							15%
SUPERETTE | Promissory Notes | Significant Advances and Adjustments
Disclosure Of Transactions Between Related Parties [Line Items]
Adjusted fair value of debt instrument								$ (3.7)
SUPERETTE | Amended and Restated Promissory Note
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument		$ 1.8		$ 8.1
SUPERETTE | Amended and Restated Promissory Note | Significant Advances and Adjustments
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument	$ 0.3
Term Loan | VALENS
Disclosure Of Transactions Between Related Parties [Line Items]
Cash Out Flow For Non Revolving Loan Issuance					$ 60
Maturity date of investments					Dec. 15, 2023
Rate of interest on investments					10%
Convertible Debenture | DELTA 9
Disclosure Of Transactions Between Related Parties [Line Items]
Debt instruments held						$ 10
Maturity date of investments						Mar. 30, 2025
Rate of interest on investments						10%

Equity-Accounted Investees - Su

Equity-Accounted Investees - Summary of Interest (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments accounted for using equity method [abstract]
Interest in joint venture	$ 519,255	$ 412,858
Interest in associate	0	0
Investments accounted for using equity method	$ 519,255	$ 412,858	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Equity-Accounted Investees - Ad

Equity-Accounted Investees - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended		24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Apr. 14, 2023
Statements [Line Items]
Capital funded			$ 514,700
Interest in associate	$ 0	$ 0	$ 0
Pathway Rx Inc [Member]
Statements [Line Items]
Proportion of ownership interest in associate	25%
SunStream [Member] | Events After Reporting Period
Statements [Line Items]
Interest in associate				$ 10,900
Sun Stream Bancorp Inc. [Member]
Statements [Line Items]
Proportion of ownership interest in joint venture	50%
Capital funded	$ 119,137	$ 395,569
Commitment To funded Capital Towards Joint Venture Monetary Instant Credit Definition	$ 538,000

Equity-Accounted Investees - _2

Equity-Accounted Investees - Summary of Interest in Joint Venture (Details) - CAD ($) $ in Thousands	12 Months Ended				24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2022
Disclosure of joint ventures [line items]
Beging Balance	$ 412,858
Capital contributions					$ 514,700
Distributions	0	$ 10,481	[1]	$ 0
Ending Balance	519,255	412,858			519,255
Sun Stream Bancorp Inc. [Member]
Disclosure of joint ventures [line items]
Beging Balance	412,858	0			0
Capital contributions	119,137	395,569
Share of net earnings (loss)	(43,002)	32,913
Share of other comprehensive income	31,923	9,878
Distributions	(1,661)	(25,502)
Ending Balance	$ 519,255	$ 412,858		$ 0	$ 519,255
[1] Adjustment to provisional amounts — refer to note 5(b) .

Equity-Accounted Investees - _3

Equity-Accounted Investees - Summary of Financial Information of SunStream (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)	$ 501,483	$ 728,175	[1]
Current liabilities	(89,361)	(65,853)	[1]
Profit (loss) from operations	(372,428)	(226,784)	[2]	$ (239,944)
Other comprehensive income	24,581	7,607		$ 600
Sundial Growers Inc [Member]
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)	5,437	789
Non-current assets	509,418	407,860
Current liabilities	(1,146)	(1,596)
Net assets and liabilities	513,709	407,053
Revenue (loss)	(35,046)	36,203
Profit (loss) from operations	(42,627)	32,841
Other comprehensive income	31,923	9,878
Total comprehensive income (loss)	$ (10,619)	$ 42,747
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Equity-Accounted Investees - _4

Equity-Accounted Investees - Summary of Financial Information of SunStream (Parenthetical) (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	[2]	Dec. 31, 2019
Disclosure of joint ventures [line items]
Cash and cash equivalents	$ 279,586	$ 558,251	[1]	$ 60,376		$ 45,337
Percentage of net assets liabilities	100%	100%
Sundial Growers Inc [Member]
Disclosure of joint ventures [line items]
Cash and cash equivalents	$ 1,500	$ 200
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade payables	$ 9,774	$ 4,172
Accrued and other liabilities	38,379	34,280
Accounts payable and accrued liabilities	$ 48,153	$ 38,452	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Derivative Warrants - Summary o

Derivative Warrants - Summary of Derivative Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Balance, beginning of year	$ 21,700	$ 428
Change in fair value recognized in profit or loss	(10,783)	(28,697)
Converted to common shares	0	(157,818)
Balance, end of year	11,002	21,700
2021 Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	62,680
2021 Additional Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	38,576
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	106,531
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	$ 85	$ 0

Derivative Warrants - Secured C

Derivative Warrants - Secured Convertible Note Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.

Derivative Warrants - Unsecured

Derivative Warrants - Unsecured Convertible Note Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.
Warrants outstanding	10,051,400
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	50,000	[1]
[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

Derivative Warrants - Series A

Derivative Warrants - Series A and Series B Warrants - Additional Information (Details)	Dec. 31, 2022 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	10,051,400
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	50,000	[1]
[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

Derivative Warrants - Summary_2

Derivative Warrants - Summary of Outstanding Derivative Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares		Dec. 31, 2022 shares $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	10,051,400		10,051,400
Weighted average contractual life	1 year 7 months 6 days
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1.77	[1]
Warrants outstanding	50,000	[1]	50,000	[1]
Weighted average contractual life	2 years 7 months 6 days	[1]
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1.77	[1]
Warrants outstanding	50,000	[1]	50,000	[1]
Weighted average contractual life	1 year	[1]
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 2.29	[2]
Warrants outstanding	9,833,333	[2]	9,833,333	[2]
Weighted average contractual life	1 year 7 months 6 days	[2]
December 2018 Performance Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares			$ 5.51
Warrants outstanding	118,067		118,067
Weighted average contractual life	1 year
[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable. The exercise price of the New Warrants was adjusted from USD $ 15.00 to $ 2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a) ).

Derivative Warrants - Summary_3

Derivative Warrants - Summary of Outstanding Derivative Warrants (Parenthetical) (Details) - $ / shares		12 Months Ended
	Jul. 26, 2022	Dec. 31, 2022
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average exercise price of warrant	$ 15	$ 2.29

Derivative Warrants - December

Derivative Warrants - December 2018 Performance Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding | shares	10,051,400
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.
December 2018 Performance Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding | shares	118,067
December 2018 Performance Warrants | Nova
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Value of market price equals or exceeds prior to expiration date of warrants	$ 19.27
Warrant exercise price	5.51
December 2018 Performance Warrants | Nova | Bottom of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price	0.05449
December 2018 Performance Warrants | Nova | Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price	$ 0.08174

Lease Liabilities - Summary of

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Lease Obligations [Line Items]
Acquisition (note 5(a), note5(c))	$ 345,351	$ 27,987
Lease payments	(27,693)	(1,008)	[1]	$ (420)
Current portion	30,206	5,701	[2]
Long-term	139,625	27,769	[2]
IFRS 16
Disclosure Of Lease Obligations [Line Items]
Balance, beginning of year	33,470	1,440
Acquisition (note 5(a), note5(c))	142,106	29,531
Additions	7,497	4,514
Lease payments	(31,834)	(2,721)
Dispositions and remeasurements	10,890	(70)
Tenant inducement allowances received	1,799
Accretion expense	5,903	776
Balance, end of year	169,831	33,470		$ 1,440
Current portion	30,206	5,701
Long-term	$ 139,625	$ 27,769
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Lease Liabilities - Summary o_2

Lease Liabilities - Summary of Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2022 CAD ($)
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 200,570
Less Than One Year
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	39,255
One to Three Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	64,892
Three to Five Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	48,955
Thereafter
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 47,468

Other Liabilities - Schedule Of

Other Liabilities - Schedule Of Other Liabilities (Detail) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Other Liabilities [Abstract]
Financial guarantee liability	$ 407	$ 466
Deferred share units liability	2,302	4,039
Total	$ 2,709	$ 4,505	[1]
[1] Adjustment to provisional amounts — refer to note 5(b) .

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense (Recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Major components of tax expense (income) [abstract]
Loss before income tax	$ (379,770)	$ (234,698)	[1],[2]	$ (206,317)
Statutory income tax rates	23%	23%		24%
Expected income tax recovery	$ (87,347)	$ (53,981)		$ (49,516)
Non-deductible share-based compensation	2,508	2,308		1,970
Non-deductible finance expense	0	2		2,130
Revaluation of the fair value of warrant liabilities	(2,461)	17,902		0
Non-controlling interest	8,167	0		0
Non-deductible portion of capital losses	7,458	5,118		0
Other non-deductible expenses	5,409	610		348
Goodwill impairment	35,919	0		0
Change in tax rates	0	0		1,528
Deferred tax benefits not recognized	23,005	20,127		43,540
Income tax (recovery) expense	$ (7,342)	$ (7,914)		$ 0
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustments to provisional amounts — refer to note 5(b)

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ 0	$ 0	$ 0
Inventory
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	23,329	20,472
Biological assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(9,451)	(9,509)
Net Investment in Subleases
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(5,363)	(6,119)
Intangible Assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(16,632)	0
Lease liabilities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(5,488)	(8,361)
Marketable Securities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	14,981	7,442
Equity Accounted Investee
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ (1,376)	$ (3,925)

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Deductible Temporary Differences (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]
Property, plant and equipment	$ 7,413	$ 81,583
Intangible assets	183	(45,256)
Share issue costs	28,926	23,835
Investments	18,239	3,300
Lease liabilities	193,691	69,865
Financial obligations and other	2,300	4,100
Non-capital losses & scientific research and experimental development	490,326	220,596
Unrecognized deductible temporary differences	$ 741,078	$ 358,023

Income Taxes - Summary of Movem

Income Taxes - Summary of Movement in Deferred Income Tax Liability (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets And Liabilities [Line Items]
Balance, beginning of year	$ 0	$ 0
Recognized in profit and loss	(7,342)	(7,914)
Recognized in other comprehensive income	7,342	7,914
Balance, end of year	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Major components of tax expense (income) [abstract]
Non-capital losses available for future periods	$ 490.3	$ 218.5

Share Capital and Warrants - Su

Share Capital and Warrants - Summary of Issued and Outstanding (Details) - CAD ($) $ in Thousands			12 Months Ended
		Jul. 25, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Share issuances, shares		10,000,000	13,300,000
Share repurchases, shares			4,300,000
Beginning balance			$ 1,329,533	$ 269,695	$ 221,198
Share issuance costs				(16,371)	(5,593)
Share repurchases			13,390
Business acquisitions			345,351	27,987
Convertible debt - conversions					63,002
Disposition of bridge farm					(10,457)
Derivative warrants exercised				277,136	55,912
Ending balance			$ 1,327,655	$ 1,329,533	$ 269,695
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Balance, beginning of year, shares			206,040,836	91,884,413
Share issuances, shares			370,179	95,680,666
Share issuance costs, shares			0	0
Share repurchases, shares			(4,252,489)
Business acquisitions, shares			32,060,135	2,443,128,000
Convertible debt - conversions, shares			0	248,875
Derivative warrants exercised, shares			0	15,214,695
Warrants exercised, shares			0	19,571,000
Employee awards exercised, shares	[1]		975,575	549,488
Balance, end of year, shares			235,194,236	206,040,836	91,884,413
Beginning balance			$ 2,035,704	$ 762,046	$ 509,654
Share issuances, carrying amount			2,870	977,425
Share issuance costs			0	(16,371)	(5,593)
Share repurchases			41,617
Business acquisitions			287,129	26,216
Convertible debt - conversions			0	2,671	63,002
Disposition of bridge farm					(38,447)
Derivative warrants exercised			0	277,136	55,912
Warrants exercised			0	178
Employee awards exercised	[1]		8,724	6,403
Ending balance			$ 2,292,810	$ 2,035,704	$ 762,046
[1] Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

Share Capital and Warrants - _2

Share Capital and Warrants - Summary of Issued and Outstanding (Parentheticals) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Share Units
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares vested	50,000	87,500

Share Capital and Warrants - Ad

Share Capital and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions				12 Months Ended
	Apr. 14, 2023 $ / shares shares	Apr. 14, 2023 $ / shares shares	Jul. 25, 2022 shares	Dec. 31, 2022 CAD ($) $ / shares shares		Dec. 31, 2022 CAD ($) $ / shares shares		Dec. 31, 2021 CAD ($) $ / shares shares		Dec. 31, 2022 USD ($)
Share Capital And Warrants [Line Items]
Number of shares issued			10,000,000	13,300,000		13,300,000
Number of shares issued upon conversion			1
Share repurchases, shares				4,300,000		4,300,000
Shares repurchased weighted average price per common share | (per share)				$ 3.12		$ 2.33
Accumulated deficit				$ (1,091,999)	[1]	$ (1,091,999)	[1]	$ (785,112)	[1]	$ 28.3
Events After Reporting Period
Share Capital And Warrants [Line Items]
Number of shares issued	1,500,000	1,500,000
Share repurchases, shares	500,000	500,000
Shares repurchased weighted average price per common share | (per share)	$ 2.78	$ 2.04
Inner Spirit Holdings Ltd
Share Capital And Warrants [Line Items]
Warrants Exercised								19,571
Net payment of warrants | $								$ 200
Sun 8 Holdings Inc
Share Capital And Warrants [Line Items]
Number of warrants issued								64,000
Warrant exercise price | $ / shares								$ 9.40
[1] Adjustment to provisional amounts — refer to note 5(b) .

Share Capital and Warrants - _3

Share Capital and Warrants - Summary of Common Share Purchase Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance	$ 1,329,533	$ 269,695
Ending balance	$ 1,327,655	$ 1,329,533
Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance, Number of Warrants	356,612	102,400
Acquisition (note 5)		209,783
Warrants issued, Number of Warrants		64,000
Warrants exercised, Number of Warrants		(19,571)
Warrants expired, Number of Warrants	(48,000)
Ending balance, Number of Warrants	308,612	356,612
Beginning balance	$ 8,092	$ 6,138
Acquisition (note 5), Carrying Amount		1,771
Warrants Issued, Carrying Amount		361
Warrants exercised, Carrying Amount		(178)
Warrants expired, Carrying Amount	(5,832)
Ending balance	$ 2,260	$ 8,092

Share Capital And Warrants - _4

Share Capital And Warrants - Summary of Outstanding Warrants (Details) - Warrants	12 Months Ended
	Dec. 31, 2022 Warrant $ / shares
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 12.13
Warrants outstanding and exercisable, Number of warrants | Warrant	308,612
Warrants outstanding and exercisable, Weighted average contractual life (years)	2 years 6 months
Sun 8 Holdings Inc
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 9.40
Warrants outstanding and exercisable, Number of warrants | Warrant	64,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	3 years
Financial Services
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 45.98
Warrants outstanding and exercisable, Number of warrants | Warrant	54,400
Warrants outstanding and exercisable, Weighted average contractual life (years)	6 years 7 months 6 days
Acquired From Inner Spirit [Member]
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 3.37	[1]
Warrants outstanding and exercisable, Number of warrants | Warrant	190,212	[1]
Warrants outstanding and exercisable, Weighted average contractual life (years)	1 year 2 months 12 days	[1]
[1] Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b) ) and have been presented based on the number of SNDL common shares that are issuable.

Share Capital And Warrants - _5

Share Capital And Warrants - Summary of Outstanding Warrants (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2022 shares
Inner Spirit
Statements [Line Items]
Warrants are Exchangeable For Number Of Common Shares Accordance With The Transaction Consideration	0.00835

Share-based Compensation - Comp

Share-based Compensation - Components of Share-based Compensation Expense (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		$ 9,671	$ 12,307	[1]	$ 8,566
Simple Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		1,299	2,899		1,539
Performance Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation			361		(42)
Stock Options | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		78	(14)		651
Restricted Share Units | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	[2]	9,423	6,789		4,069
Deferred Share Units | Cash Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	[2],[3]	$ (1,129)	$ 2,272		$ 2,349
[1] Adjustment to provisional amounts — refer to note 5(b) . For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $ 107 and share-based compensation expense under Nova’s DSU plan of $ 404 . Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.

Share-based Compensation - Co_2

Share-based Compensation - Components of Share-based Compensation Expense (Parenthetical) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 9,671	$ 12,307		$ 8,566
NOVA RSU PLAN | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation recovery	107
NOVA DSU PLAN | Cash Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 404
[1] Adjustment to provisional amounts — refer to note 5(b) .

Share-based Compensation - Addi

Share-based Compensation - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($) shares	Dec. 31, 2021 CAD ($) shares	Dec. 31, 2020 shares
Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Fair value of cash settled deferred share units | $	$ 2.3	$ 4
Simple and Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period	3 years
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period	5 years
Exercised		12,000
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period	5 years
Exercised		8,000
Stock Options | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period	3 years
Maturity period	10 years
Restricted Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercised		50,000	87,500
Restricted Share Units | Long-term Incentive Program
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	7,800,000
Restricted Share Units | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	1,728,557	1,238,152
Exercised	925,575	491,988
Deferred Share Units | Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	1,216,076	248,919
Exercised	58,943	30,000
Vesting term	DSUs are granted to directors and generally vest in equal instalments over one year
Vesting period	1 year
Stock options, Exercisable	0	600,000

Share-based Compensation - Summ

Share-based Compensation - Summary of Changes in Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	259,420	342,460
Forfeited | shares	(82,400)	(66,880)
Exercised | shares		(12,000)
Expired | shares	(11,200)	(4,160)
Ending balance | shares	165,820	259,420
Weighted average exercise price, beginning balance	$ 48.60	$ 44.13
Weighted average exercise price, Forfeited	57.77	33.62
Weighted average exercise price, Exercised		9.38
Weighted average exercise price, Expired	6.25	34.51
Weighted average exercise price, ending balance	$ 46.91	$ 48.60
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	138,720	167,200
Forfeited | shares	(15,520)	(20,480)
Exercised | shares		(8,000)
Ending balance | shares	123,200	138,720
Weighted average exercise price, beginning balance	$ 41.77	$ 41.89
Weighted average exercise price, Forfeited	37.86	54.80
Weighted average exercise price, Exercised		10.94
Weighted average exercise price, Expired	0	0
Weighted average exercise price, ending balance	$ 42.26	$ 41.77

Share-based Compensation - Su_2

Share-based Compensation - Summarizes Outstanding Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	165,820	259,420	342,460
Weighted average exercise price, Warrants outstanding | $ / shares	$ 46.91	$ 48.60	$ 44.13
Weighted average contractual life, Warrants outstanding (years)	2 years 5 months 26 days
Number of warrants, Warrants exercisable | shares	158,620
Weighted average exercise price, Warrants exercisable | $ / shares	$ 37.68
Weighted average contractual life, Warrants exercisable (years)	2 years 4 months 9 days
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	123,200	138,720	167,200
Weighted average exercise price, Warrants outstanding | $ / shares	$ 42.26	$ 41.77	$ 41.89
Number of warrants, Warrants exercisable | shares	106,134
Weighted average exercise price, Warrants exercisable | $ / shares	$ 19.28
Weighted average contractual life, Warrants exercisable (years)	1 year 10 months 28 days
$6.25 - $9.38 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	75,340
Weighted average exercise price, Warrants outstanding | $ / shares	$ 7.25
Weighted average contractual life, Warrants outstanding (years)	1 year 4 months 24 days
Number of warrants, Warrants exercisable | shares	75,340
Weighted average exercise price, Warrants exercisable | $ / shares	$ 7.25
Weighted average contractual life, Warrants exercisable (years)	1 year 4 months 24 days
$6.25 - $9.38 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	45,066
Weighted average exercise price, Warrants outstanding | $ / shares	$ 6.71
Number of warrants, Warrants exercisable | shares	45,066
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.71
Weighted average contractual life, Warrants exercisable (years)	2 years
$12.50 - $18.75 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	17,334
Weighted average exercise price, Warrants outstanding | $ / shares	$ 15.15
Number of warrants, Warrants exercisable | shares	17,334
Weighted average exercise price, Warrants exercisable | $ / shares	$ 15.15
Weighted average contractual life, Warrants exercisable (years)	11 months 4 days
$29.69 - $45.31 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	27,120
Weighted average exercise price, Warrants outstanding | $ / shares	$ 31.26
Weighted average contractual life, Warrants outstanding (years)	1 year 7 months 9 days
Number of warrants, Warrants exercisable | shares	26,320
Weighted average exercise price, Warrants exercisable | $ / shares	$ 31.02
Weighted average contractual life, Warrants exercisable (years)	1 year 6 months 14 days
$29.69 - $45.31 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	42,400
Weighted average exercise price, Warrants outstanding | $ / shares	$ 31.99
Number of warrants, Warrants exercisable | shares	42,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 31.99
Weighted average contractual life, Warrants exercisable (years)	1 year 2 months 19 days
$62.50 - $93.75 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	49,920
Weighted average exercise price, Warrants outstanding | $ / shares	$ 63.50
Weighted average contractual life, Warrants outstanding (years)	4 years 18 days
Number of warrants, Warrants exercisable | shares	49,920
Weighted average exercise price, Warrants exercisable | $ / shares	$ 63.50
Weighted average contractual life, Warrants exercisable (years)	4 years 18 days
$62.50 - $93.75 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	9,334
Weighted average exercise price, Warrants outstanding | $ / shares	$ 77.68
Number of warrants, Warrants exercisable | shares	1,334
Weighted average exercise price, Warrants exercisable | $ / shares	$ 93.75
Weighted average contractual life, Warrants exercisable (years)	1 year 1 month 6 days
$125.00 - $375.00 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	13,440
Weighted average exercise price, Warrants outstanding | $ / shares	$ 239.15
Weighted average contractual life, Warrants outstanding (years)	4 years 7 months 13 days
Number of warrants, Warrants exercisable | shares	7,040
Weighted average exercise price, Warrants exercisable | $ / shares	$ 205.18
Weighted average contractual life, Warrants exercisable (years)	3 years 8 months 12 days
$125.00 - $375.00 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	9,066
Weighted average exercise price, Warrants outstanding | $ / shares	$ 282.36

Share-based Compensation - Su_3

Share-based Compensation - Summary of Changes in Stock Options (Details) - Equity Settled Plan - Stock Options	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning Balance | shares	44,460	72,060
Forfeited | shares		(27,500)
Expired | shares	(100)	(100)
Ending Balance | shares	44,360	44,460
Weighted average exercise price, beginning balance | $ / shares	$ 13.28	$ 18.18
Weighted average exercise price, Forfeited | $ / shares		26.05
Weighted average exercise price, Expired | $ / shares	31.50	31.50
Weighted average exercise price, ending balance | $ / shares	$ 13.24	$ 13.28

Share-based Compensation - Su_4

Share-based Compensation - Summary of Outstanding Stock Options (Details) - Equity Settled Plan - Stock Options - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	44,360	44,460	72,060
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 3 months 7 days
Number of options, Stock options exercisable	32,852
Weighted average contractual life, Stock options exercisable (years)	7 years 2 months 26 days
$11.50
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	32,500
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 4 months 28 days
Number of options, Stock options exercisable	21,667
Weighted average contractual life, Stock options exercisable (years)	7 years 4 months 28 days
$11.90
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	8,160
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 5 months 26 days
Number of options, Stock options exercisable	8,160
Weighted average contractual life, Stock options exercisable (years)	7 years 5 months 26 days
$31.50
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	3,700
Warrants outstanding and exercisable, Weighted average contractual life (years)	5 years 6 months 3 days
Number of options, Stock options exercisable	3,025
Weighted average contractual life, Stock options exercisable (years)	5 years 4 months 17 days

Share-based Compensation - Su_5

Share-based Compensation - Summary of Changes in Restricted Share Units (Details) - Restricted Share Units - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercised		(50,000)	(87,500)
Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	753,593	165,692
Granted	1,728,557	1,238,152
Forfeited	(175,245)	(158,263)
Exercised	(925,575)	(491,988)
Ending balance	1,381,330	753,593	165,692

Share-based Compensation - Su_6

Share-based Compensation - Summary of Changes in Deferred Share Units (Details) - Cash Settled Plan - Deferred Share Units - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	551,250	332,331
Granted	1,216,076	248,919
Exercised	(58,943)	(30,000)
Ending balance	1,708,383	551,250

Gross Revenue - Disaggregation

Gross Revenue - Disaggregation of Revenue from Contracts with Customers (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 729,694	$ 67,279	$ 73,321
Liquor retail revenue
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	462,180	0	0
Cannabis retail revenue
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	205,610	16,091	0
Cannabis retail revenue | Retail
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	192,710	10,207	0
Cannabis retail revenue | Franchise
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	8,337	4,251	0
Cannabis retail revenue | Other
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	4,563	1,633	0
Cannabis
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	61,904	51,188	73,321
Cannabis | Provincial Boards
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	58,728	41,338	55,315
Cannabis | Medical
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	9	8	32
Cannabis | Wholesale
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 3,167	$ 9,842	$ 17,974

Gross Revenue - Summary of Rece

Gross Revenue - Summary of Receivables from Contracts with Customers (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue [abstract]
Receivables, included in 'trade receivables' (note 9)	$ 17,558	$ 10,865	$ 15,786

Gross Revenue - Additional Info

Gross Revenue - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue [abstract]
Maximum period to settle receivables from contracts with customers	30 days
Impairment loss (reversal) on receivables from contracts with customers	$ 0.6	$ 0.2

Investment Revenue (Loss) - Sum

Investment Revenue (Loss) - Summary of Interest and Fee Revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Revenue (Loss) [Abstract]
Interest revenue from investments at amortized cost	$ 3,660	$ 1,654	$ 0
Interest and fee revenue from investments at FVTPL	6,036	8,514	0
Interest revenue from cash	7,043	2,981	0
Interest and fee revenue	$ 16,739	$ 13,149	$ 0

Investment Revenue (Loss) - S_2

Investment Revenue (Loss) - Summary of Investment Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Loss [Abstract]
Realized gains	$ 389	$ 20,213	$ 0
Unrealized (losses) gains (note 8)	(65,553)	(64,714)	0
Investment loss	$ (65,164)	$ (44,501)	$ 0

Other Operating Expenses - Summ

Other Operating Expenses - Summary of General and Administrative Expense (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Expenses by nature [abstract]
Salaries and wages		$ 80,134	$ 18,675	[1]	$ 11,634
Consulting fees		1,934	1,112	[1]	2,193
Office and general		37,061	7,560	[1]	9,843
Professional fees		11,563	6,530	[1]	4,658
Merchant Processing Fees		4,748
Director fees		472	351	[1]	365
Other		4,256	3,815	[1]	3,336
General and administrative expense	[2]	$ 140,168	$ 38,043		$ 32,029
[1] Adjustment to provisional amounts — refer to note 5(b) . Adjustment to provisional amounts — refer to note 5(b) .

Other Operating Expenses - Su_2

Other Operating Expenses - Summary of Sales and Marketing Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Expenses by nature [abstract]
Marketing	$ 7,308	$ 3,671		$ 4,839
Events	102	191		393
Research		43		57
Media	1,007	1,138		448
Sales and marketing expense	$ 8,417	$ 5,043	[1]	$ 5,737
[1] Adjustment to provisional amounts — refer to note 5(b) .

Government Subsidies - Addition

Government Subsidies - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy	$ 2,180	[1]	$ 4,128
[1] Adjustment to provisional amounts — refer to note 5(b) .

Finance Costs - Summary of Fina

Finance Costs - Summary of Finance Costs (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash finance expense
Interest on long-term debt				$ 7,482
Other finance costs	$ 178	$ 40		286
Interest expense	178	40		7,768
Non-cash finance expense (income)
Change in fair value of investment at FVTPL	36,087	3,300
Accretion on lease liabilities	5,903	776		89
Financial guarantee liability (recovery) expense	(59)	59
Accretion				1,622
Amortization of debt issue costs				1,782
Change in fair value of convertible notes				(7,141)
Other	89	154		(86)
Non-cash finance expense (income)	42,020	4,289		(3,734)
Interest income	(884)	(573)		(215)
Finance costs	$ 41,314	$ 3,756	[1]	$ 3,819
[1] Adjustment to provisional amounts — refer to note 5(b) .

Supplemental Cash Flow Disclo_3

Supplemental Cash Flow Disclosures - Summary of Changes in Non-cash Working Capital (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash provided by (used in):
Accounts receivable	$ (5,815)	$ 9,339		$ (2,037)
Biological assets	533	3,829		13,789
Inventory	4,243	(18,318)		(12,315)
Prepaid expenses and deposits	5,782	(3,922)		2,280
Investments	918	(402)
Right of use assets	(17,510)
Property, plant and equipment	38	(305)
Accounts payable and accrued liabilities	(27,864)	9,665		(20,793)
Lease liabilities	19,296
Changes in non cash working capital	(20,379)	(114)		(19,076)
Changes in non-cash working capital relating to:
Operating	(22,073)	150	[1]	(5,259)
Investing	74	(612)	[1]	(11,319)
Financing	1,620	348	[1]	(2,498)
Changes in non cash working capital	$ (20,379)	$ (114)		(19,076)
Cash interest paid				$ 6,094
[1] Adjustment to provisional amounts — refer to note 5(b) .

Loss Per Share - Summary of Los

Loss Per Share - Summary of Loss Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Weighted average shares outstanding (000s)
Basic and dilutive	[1]	229,871	186,038		21,865
Continuing operations
Net loss attributable to owners of the Company	[2]	$ (335,114)	$ (226,984)		$ (199,619)
Per share - basic and diluted		$ (1.46)	$ (1.22)		$ (9.13)
Discontinued operations
Net loss attributable to owners of the Company					$ (33,627)
Per share - basic and diluted					$ (1.54)
Net loss attributable to owners of the Company	[2]	$ (335,114)	$ (226,984)		$ (233,246)
Per share - basic and diluted		$ (1.46)	$ (1.22)	[2]	$ (10.67)
[1] For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs t hat were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs). Adjustment to provisional amounts — refer to note 5(b) .

Loss Per Share - Summary of L_2

Loss Per Share - Summary of Loss Per Share (Parenthetical) (Details) - CAD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings per share [abstract]
Equity Classified warrants	0.3	0.4	0.1
Derivative warrants	10.1	9.9	0.2
Simple warrants	0.2	0.3	0.3
Performance warrants	0.1	0.1	0.2
Stock options	$ 40	$ 40	$ 70
RSUs Exercisable	$ 1,400	$ 800	$ 200

Financial Instruments - Summary

Financial Instruments - Summary of Fair Value Measurements of Long-term Debt, Derivative Warrant Liabilities and Contingent Consideration (Details) - Recurring fair value measurement [member] - CAD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		$ 21,926	$ 83,724
Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		72,761	48,576
Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	11,002	21,700
Level 1 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		21,926	83,724
Level 1 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 1 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	0	0
Level 2 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 2 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 2 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	0	0
Level 3 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 3 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		72,761	48,576
Level 3 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	$ 11,002	$ 21,700
[1] The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($)
Disclosure Of Financial Instruments [Line Items]
Percentage of change in material assumptions	10%
Financial instruments expected credit loss	$ 0.5
Marketable Securities
Disclosure Of Financial Instruments [Line Items]
Threshold Percentage of Change in Market Prices Would Effect Fair Value of Marketable Securities	10%
Change in Fair Value of Securities	$ 2.1
Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Change in fair value liabilities	$ 1.3

Financial Instruments - Summa_2

Financial Instruments - Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Impairment loss (reversal) on trade receivables	$ 642	$ 214
Impairment loss (reversal) on other receivables	674	798
Impairment loss (reversal) on accounts receivable	$ 1,316	$ 1,012

Financial Instruments - Summa_3

Financial Instruments - Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Balance, beginning of year	$ 1,132	$ 120
Net remeasurement of impairment loss allowance	1,316	1,012
Balance, end of year	$ 2,448	$ 1,132

Financial Instruments - Timing

Financial Instruments - Timing of Expected Cash Outflows Relating to Financial Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	[1]
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	$ 48,153	$ 38,452
Liquidity Risk Management
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	48,153
Financial guarantee liability	407
Balance, end of year	48,560
Liquidity Risk Management | Less Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	48,153
Financial guarantee liability	0
Balance, end of year	48,153
Liquidity Risk Management | One to Three Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	407
Balance, end of year	407
Liquidity Risk Management | Three to Five Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	0
Balance, end of year	0
Liquidity Risk Management | Thereafter
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	0
Balance, end of year	$ 0
[1] Adjustment to provisional amounts — refer to note 5(b) .

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Related party transactions [abstract]
Related party transaction, terms		The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037.
Total rent	$ 117,900

Related Party Transactions - Co

Related Party Transactions - Compensation of Key Management Personnel (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of transactions between related parties [abstract]
Salaries and short-term benefits	$ 4,505	$ 2,348	$ 1,944
Share-based compensation	5,871	8,275	7,629
Key management personnel compensation	$ 10,376	$ 10,623	$ 9,573

Non-Controlling Interests - Sum

Non-Controlling Interests - Summarized Statement of Financial Position (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	[1]
Disclosure of subsidiaries [line items]
Current assets	$ 501,483	$ 728,175
Current liabilities	89,361	$ 65,853
Nova [Member]
Disclosure of subsidiaries [line items]
Current assets	18,732
Current liabilities	19,892
Current net assets	(1,160)
Non-current assets	94,419
Non-current liabilities	45,443
Non-current net assets	48,976
Net assets and liabilities	$ 47,816
[1] Adjustment to provisional amounts — refer to note 5(b) .

Non-Controlling Interests - S_2

Non-Controlling Interests - Summarized Statement of Loss and Comprehensive Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Revenue	$ 712,197	$ 56,128		$ 60,918
Nova [Member]
Disclosure of subsidiaries [line items]
Revenue	176,588
Loss and comprehensive loss	$ (7,672)
[1] Adjustment to provisional amounts — refer to note 5(b) .

Non-Controlling Interests - S_3

Non-Controlling Interests - Summarized Statement of Cash Flows (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Net cash provided by operating activities	$ (6,711)	$ (155,752)		$ (57,495)
Net cash used in investing activities	(230,164)	(496,280)		(70,877)
Net cash used in financing activities	(41,790)	1,149,916		142,746
Change in cash and cash equivalents	(278,665)	$ 497,875		$ 15,039
Nova [Member]
Disclosure of subsidiaries [line items]
Net cash provided by operating activities	5,848
Net cash used in investing activities	(5,549)
Net cash used in financing activities	(183)
Change in cash and cash equivalents	$ 116
[1] Adjustment to provisional amounts — refer to note 5(b) .

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Commitments And Contingencies [Abstract]
Accrued financial penalties payable	$ 2.5	$ 2.5

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ in Thousands, shares in Millions, $ in Millions	Mar. 28, 2023 CAD ($) Store	Aug. 22, 2022 CAD ($) shares	Mar. 06, 2023 USD ($)
Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Investments interest rate		10%
Investments maturity date		Dec. 15, 2023
non-revolving term loan facility		$ 60
Bankruptcy Transaction
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Superpriority secured debtor-in-possession line of credit			$ 1,750
Lightbox Enterprises Ltd. | Major Business Combination | Lightbox Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of retail stores | Store	4
Total consideration	$ 7.8
Cash consideration	1.5
Issuance of common shares	3.3
Cancellation of debt	$ 3
VALENS | Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
non-revolving term loan facility		$ 60
VALENS | Major Ordinary Share Transactions | Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of units issued | shares		27.6
Aggregate shares issued,value		$ 84
Common stock ,conversion price		0.3334